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ABSTRACT 
 
Multi-Dimensional Analysis of HDL: An Approach  
to Understanding Atherogenic HDL. 
 (December 2008) 
Jeffery Devoyne Johnson Jr., B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Ronald D. Macfarlane 
 
 Density gradient ultracentrifugation (DGU) is a powerful method for analyzing 
lipoprotein particles in great detail.  It yields considerable amounts of information 
regarding the density distribution of these particles when coupled with fluorometric 
analysis and is an invaluable tool in determining their relative abundance.  This union 
allows relationships between subclasses of lipoproteins to be established that gives 
researchers a more focused path to aid them in developing methods to predict the early 
onset of coronary artery disease (CAD).  The research presented here focuses on the 
pairing of DGU with post-separatory techniques including matrix-assisted laser 
desorption mass spectrometry (MALDI-MS), liquid chromatography mass spectrometry 
(LC-MS), capillary electrophoresis (CE), isoelectric focusing (IEF) and apoptosis studies 
involving cell cultures.   
It is becoming clearer that cholesterol concentrations themselves do not provide 
sufficient data to assess the quality of cardiovascular health.  As a result, research is 
becoming more focused on identifying better markers that may be indicative of 
development of CAD in a patient.  Of specific interest is group of particles known as 
high density lipoproteins (HDL).  Classically, this molecule is considered the “good 
cholesterol”, but literature from the last decade suggests that there may be atherogenic 
variants to this group.  By utilizing DGU as a preparatory method for secondary 
analyses, new dimensions can be added to the density distribution analysis to allow a 
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better determination of markers of cardiovascular health. The aim of this work is to 
utilize the principles involved with these various techniques to develop a comprehensive 
set of methods to aid in the detection of potential risk markers. 
In this study, the properties of metal ion complexes of EDTA as solute systems 
for analysis of lipoproteins by DGU are analyzed.  We show that by varying the 
complexing ion and counter-ion of these metal-ion complexes, we gain the ability to 
control the separation of lipoprotein subclasses for subsequent analyses.  Qualitative and 
quantitative data is presented that describes the analysis of different density regions of 
HDL for apolipoprotein content.  Trends between control and atherogenic samples are 
also described and a clinical link between the biological activity of these regions and the 
chemical analysis is discussed. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Significance 
 In a sample of human serum there is a distribution of nanoparticles on the 
micromolar level known as lipoproteins that play key roles in the metabolism and 
transportation of lipids, triglycerides, cholesterols and their corresponding esters.  In the 
diagnosis of coronary artery disease (CAD), it is important to evaluate the composition 
of serum for potential risk factors such as high concentration of low density lipoprotein 
(LDL), low concentration of high density lipoprotein (HDL), or the presence of 
potentially atherogenic proteins such as Apo C-I and Lp(a).1   
One manner of separating and identifying lipoprotein particles is through the use 
of density gradient ultracentrifugation (DGU).  In DGU, particles migrate to their 
isopycnic point during a spin at high speeds resulting in a lipoprotein density profile.  
Since different classifications of lipoprotein particles are defined by their hydrated 
densities, DGU is the primary tool of analysis in the field of lipoproteomics.2  The 
different regions of the lipoprotein density profile can be enhanced by optimizing 
parameters such as the molecular weight of the density gradient-forming solute, its 
concentration, or the spin time.3, 4  By utilizing these principles it becomes possible to 
isolate desired subclasses for further study.   
Another analytical technique that yields information regarding the size/charge of 
the molecular system being studied is mass spectrometry.  In this technique, the sample 
is ionized through a variety of means including electron ionization5, chemical 
ionization6, secondary ion mass spectrometry (SIMS)7, electrospray ionization (ESI)8, 
and matrix-assisted laser desorption ionization (MALDI).9   
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The latter two are the most common in protein analysis since a soft ionization technique 
is desired to prevent excessive fragmentation of the molecules of interest. 
Capillary electrophoresis (CE) is another useful analytical tool for the study of 
lipoproteins.10, 11  By varying the properties of the buffer system to be used, lipoproteins 
can be analyzed in both their nascent and delipidated forms to give information 
regarding the size/charge of the intact molecule and their  associated apolipoproteins.12 
The effective electrophoretic mobility for various subclasses can be determined for 
comparison between samples by analyzing the movement of lipoprotein particles in a 
buffer under the influence of an applied electric field.  Molecules possessing different 
electrophoretic mobilities will travel at different rates, so this technique gives a second 
degree of separation after DGU. 
 Isoelectric focusing (IEF) is a very useful technique that utilizes differences in 
the inherent charge states of proteins in buffered solution.  By introducing proteins into a 
gel matrix that contains a continuous pH gradient and then applying a potential, proteins 
can be separated based on mobility due to differences in their respective isoelectric 
points (pI).13  Using this method, complex mixtures of macromolecules, such as the 
distribution of apolipoproteins inherent in HDL, can be separated with high resolution.14 
This work utilizes the techniques of DGU, MS, CE, and IEF to develop a unified 
method for identifying new risk factors, particularly those regarding atherogenic HDL, 
for the early detection of CAD.   
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1.2 Structural and Functional Description of Lipoproteins 
Lipoprotein particles are biochemical assemblies of lipids and proteins that are 
responsible for the transport of lipids in the bloodstream and are classified primarily 
based on their respective densities (Table 1).15   
 
Table 1.  Lipoprotein Characteristics 
Class Density (g/mL) Size (nm) Major Lipids Major Apolipoproteins
Chylomicrons < 0.93 100 - 500 Dietary TAGs B-48, C-II, E 
VLDL 0.93 -1.006 30 - 80 Endogenous TAGs B-100, C-II, E 
IDL 1.006 -1.019 25 - 50 CEs and TAGs B-100, E 
LDL 1.019 -1.063 18 - 28 CEs and TAGs B-100 
HDL 1.063 -1.210 5 - 15 PL A, C-II, E 
Lp(a) 1.040 -1.090 25 - 30 CEs B-100, Glycoprotein 
 
This classification is only relative to the condition of a lipoprotein in the lipid metabolic 
cycle since they are constantly in flux between identities and roles.16  Lipoproteins are 
water-soluble macromolecules that contain a hydrophilic exterior surrounding a 
hydrophobic core and are very similar to micelles in structure (Figure 1). 
 
 
Figure 1. Basic Composition of a Lipoprotein 
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Encasing the lipid core is a shell of tightly packed phospholipids and cholesterol that is 
oriented in such a way that the polar groups extend outward and the hydrophobic tails 
point inward. 
There is also a relationship between the density of lipoproteins and the biological 
role they play in lipid metabolism.  Lipoprotein particles with lower densities have a 
higher lipid composition whereas denser lipoproteins have a higher protein composition.  
Chylomicrons, also known as buoyant triglyceride-rich lipoprotein (bTRL), are secreted 
by the small intestine and are responsible for the transport of exogenous lipids to the 
liver, adipose tissue, and muscle.  In the case of the lipid transport lipoprotein, VLDL, 
also known as dense triglyceride-rich lipoprotein (dTRL), several exchanges of 
apolipoproteins with HDL and interactions with lipoprotein lipase (LPL) occur.  This 
causes it to lose much of its lipid content and become IDL then eventually LDL, which 
are progressively denser molecules.  Though their densities are similar, chylomicrons 
possess the apolipoprotein Apo B-48 which is a truncated form of Apo B-100 that 
VLDL contains.  LDL is responsible for the transport of cholesterol and cholesteryl 
esters from the liver to tissues in the body while HDL is responsible for transporting 
these particles from tissues back to the liver in a process known as reverse cholesterol 
transport.  The only apolipoprotein that is typically found on an LDL particle is Apo B-
100, whereas HDL can contain an array of various apolipoproteins, though to be 
classified as HDL, a molecule of Apo A-1 must be present.   
 
1.2.1 Lipoprotein Subclasses 
In addition to the standard lipoprotein classes of VLDL, LDL, and HDL there are 
also subclasses of these groups that can serve as important markers of cardiovascular 
health, making it important to isolate these various molecules for further study.  There 
are two subclasses of triglyceride-rich lipoproteins, five subclasses of LDL, and five 
subclasses of HDL that are assigned based on their respective densities as defined by 
sequential flotation (Table 2).17   
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Table 2. Densities of Lipoprotein Subclasses 
Lipoprotein Subclass Density (g/mL) 
bTRL < 1.000 
dTRL 1.000 - 1.019 
LDL-1 1.019 - 1.023 
LDL-2 1.023 - 1.029 
LDL-3 1.029 - 1.039 
LDL-4 1.039 - 1.050 
LDL-5 1.050 - 1.063 
HDL-2b 1.063 - 1.091 
HDL-2a 1.091 - 1.110 
HDL-3a 1.110 - 1.133 
HDL-3b 1.133 - 1.156 
HDL-3c 1.156-  1.179 
 
The triglyceride-rich lipoprotein subclasses are so named based upon their 
interaction with water following a density gradient separation; the buoyant fraction will 
float to the surface while the dense fraction will not.  The buoyant fraction is composed 
primarily of chylomicrons and chylomicron remnants while the dense class is composed 
of VLDL and VLDL remnants, also known as intermediate density lipoprotein (IDL). 
Remnant lipoprotein particles are also important subclasses of lipoproteins that can play 
a significant role in impacting the cardiovascular health of an individual.  Chylomicron 
remnants are essentially what are leftover after the triglyceride components from 
chylomicrons are unloaded by the activity of lipoprotein lipase.  IDL is a remnant of 
VLDL hydrolysis and typically serves as a short-lived intermediate before being cleared 
by endocytosis or conversion into LDL.2  These remnant particles tend to be smaller than 
their nascent structures and are mostly depleted of triglycerides, phospholipids, and Apo 
A and Apo C, and are enriched with cholesterol, cholesteryl esters, and apo E.18  Their 
small size gives these types of particles an increased ability to penetrate into the arterial 
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wall for foam cell formation and should be considered an independent risk factor for the 
development of CAD. 
The LDL subclasses are defined solely by their densities which reflect the 
relative amounts of cholesteryl ester and triacylglycerol present in each.  Typically, two 
main phenotypes are recognized: phenotype A which is composed of predominately 
large, buoyant LDL, and phenotype B which is composed of predominately small, dense 
LDL.19, 20  Particles of the most predominant LDL subclass in each phenotype have 
estimated diameters of greater or less than 25nm respectively for phenotypes A and B.  
Studies of family genetics have also linked the LDL distribution in phenotype B to the 
presence of a single major gene. 21, 22  Beyond these two main phenotypes, various 
degrees of further separation have been achieved, including the attainment of seven LDL 
subclasses by gradient gel electrophoresis (GGE)23, and five LDL subclasses by DGU in 
our own laboratory.  The principle difference between these different subclasses is lipid 
composition; as the LDL particles become smaller and denser, they carry with them an 
increased atherogenic risk due to their ability to more readily penetrate into the arterial 
wall. 
The HDL subclasses are split into two functionally distinct categories: the 
buoyant HDL-2 group and the dense HDL-3 group, and then are further subdivided into 
density distinct subclasses.  The lipid-deficient HDL-3 is typically converted into the 
more lipid-rich HDL-2 during the lipolysis of VLDL by hepatic lipoprotein lipase.24  
Another important distinction is that while both categories of HDL contain Apo A-I, 
only HDL-3 typically contains both Apo A-I and Apo A-II.  While the general consensus 
seems to be that having a lipid profile containing a high concentration of HDL is 
desirable, there is currently a considerable amount of disagreement as to the true role of 
HDL in the development of CAD.  There have been studies linking atherosclerosis25 and 
myocardial infarction26 with levels of HDL-2 cholesterol.  There have also been clinical 
studies that show a strong relationship between HDL-3 cholesterol and cardiovascular 
risk.27  Though these studies would imply that there are only two subclasses of HDL 
cholesterol, in actuality there are at least five by DGU and at least seventeen by IEF.28, 29  
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Ambiguity in this area lends itself to the importance of developing a method that is 
capable of thoroughly and accurately analyzing HDL to better understand its role in 
cardiovascular risk.   
 
1.2.2 Major Apolipoprotein Components of HDL 
Common risk factors for the development of CAD include:  high levels of LDL 
cholesterol (greater than 160 mg/dL), high total cholesterol (greater than 200 mg/dL), 
low HDL cholesterol (less than 60 mg/dL), cigarette smoking, hypertension, family 
history, and age.30  The objective of the study reported here is to examine serum samples 
for non-traditional risk factors with an emphasis on the apolipoprotein composition of 
HDL.  It is currently suspected that there are atherogenic variants of HDL, usually 
known as the cardio-protective “good cholesterol,” that may actually serve a role in the 
early development of CAD.   
 At any given time, a sample of serum contains a heterogeneous distribution of 
HDL molecules of various apolipoprotein compositions.  The defining apolipoprotein of 
HDL is apo A-1, which serves as a the backbone of the HDL particle and has a high lipid 
binding capacity.31  It exists as a 28,078.6 Da protein and serves in cholesterol transport 
through the activation of the enzyme lecithin:cholesterol acyltransferase (LCAT) which 
causes esterification of fatty acids from phosphatidylcholine to the 2-hydroxyl group of 
cholesterol.32, 33   
In addition to apo A-I, the apolipoprotein A-II is another protein that is present in 
considerable abundance and helps to provide structure for the HDL molecule.31  Apo A-
II exists as a dimer of two 77 amino acid monomers that are linked together by a 
disulfide bridge and has a molecular weight of 17,379.8 Da.34  It is synthesized in the 
liver and can act to displace apo A-I from HDL or even to form nascent HDL particles 
primarily containing only apo A-II.35, 36  This apolipoprotein has also been determined to 
have a negative influence on reverse cholesterol transport and may contribute to the 
development of atherosclerosis when expressed in high abundance.36-38   
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Apo C-I is a much smaller apolipoprotein that is associated with HDL, composed 
of 57 amino acids and having a molecular weight of only 6630.6 Da.31  Apo C-I can also 
be found in molecules of VLDL and even in chylomicrons though it is synthesized in the 
liver.39, 40  It is mainly responsible for the activation of LCAT, but may also promote 
atherosclerosis due to its role in displacing apo E from the HDL molecule.37, 41, 42  Apo E 
is required in the binding of β-VLDL to the LDL-receptor protein, but is hindered by apo 
C-I, thereby interfering with the clearance of triglyceride-rich lipoproteins (TRL) in the 
liver.42  Apo C-I also inhibits cholesterol ester transfer protein (CETP), which is 
responsible for lipid transfer between lipoprotein particles, and lipoprotein lipase (LPL), 
which hydrolizes lipids in lipoproteins.43-45  In normolipidemic individuals, the serum 
concentration is about 6 mg/mL.46  However, an increased concentration of apo C-I may 
be a marker for the development of CAD.47, 48 
Some other important apolipoprotein components of HDL that are present in low 
abundance include:  apo C-II, apo C-III, and apo E, each with their own unique roles in 
lipid metabolism.  Apo C-II is a 8914.2 Da protein that is responsible mainly for the 
activation of LPL and LCAT.49, 50  A deficiency of this protein impairs plasma clearance 
of triglycerides and can cause hypertriglyceridemia.51  Apo C-III is a 79 amino acid 
protein that exhibits three masses that are dependent on the degree of sialation at the 74th 
position and ranging in molecular weight from 8764.7 Da to 9712.6 Da.31  Its main roles 
are in the modulation of the uptake of TRL remnants by the liver receptors, and in the 
inhibition of LPL and hepatic triglyceride lipase (HTGL).45, 52-55   High concentrations of 
apo C-III have been shown to increase the progression of atherosclerosis and also 
recurrence of cardiac events.56-58  Apo E is a 299 amino acid protein that also exhibits 
three masses that differ at the 112th and 158th positions and ranges in molecular weight 
from 34183.6 to 34928.8 Da.31, 59, 60  It has many roles in lipoprotein metabolism, 
including:  mediation of remnant TRL and cholesterol uptake in the liver through apo E 
receptor recognition, redistribution of lipids in tissue, formation of cholesterol ester-rich 
HDL particles, and binding of heparin.31, 61-63  Elevated levels of apo E correlate with 
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hypertriglyceridemia while a deficiency correlates with increased levels of TRL 
remnants.64, 65   
  
1.2.3 Markers of Cardiovascular Risk 
In a healthy lipid profile, an individual traditionally expresses low total 
cholesterol with a low level of LDL cholesterol and a high level of HDL cholesterol.  
Conversely, an individual with an atherogenic lipoprotein phenotype expresses a high 
total cholesterol with elevated VLDL and LDL, particularly LDL-3 cholesterol, and a 
low level of HDL cholesterol.  HDL is known to play a role in maintaining a healthy 
lipid metabolism, but recent evidence suggests that there are forms of HDL that can 
actually contribute to CAD risk in an individual.66  Previous research also shows that 
there is a form of HDL that is rich in Apo C-I that was found in infants that were small 
for gestational age (SGA) who tend to prematurely develop CAD later in life.67  
Normally, Apo C-I is an apolipoprotein of HDL that is responsible for the inhibition of 
cholesterol ester transfer protein (CETP) and is important to the regulation of cholesterol 
transport, but it is currently a suspected independent risk marker for early onset of 
CAD.47, 48, 67, 68 
 
1.3 Current Methods of Analysis 
Several commercial methods of analyzing lipoproteins have been developed, 
such as: gradient gel electrophoresis (GGE), tube gel electrophoresis (TGE), 
ultracentrifugation-vertical auto profile (VAP), and nuclear magnetic resonance (NMR).  
Unfortunately, the low amount of agreement between the results of these techniques 
warrants more accurate and precise methods of analysis.69 
    In gel electrophoresis techniques, molecules are separated based on physical 
characteristics such as size, shape, or pI and can be used as a preparative tool for other 
techniques like mass spectrometry, sequencing, or blotting.70  Krauss and coworkers 
have utilized GGE to investigate the small dense class of LDL that is associated with 
familial combined hyperlipidemia (FCHL). 71  This is a genetic disorder of lipid 
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metabolism usually associated with elevated cholesterol levels, high LDL concentration, 
and diminished HDL concentration.  It was found that there is a bi-modal distribution of 
LDL size among patients that can be associated with two metabolically distinct 
phenotypes: pattern A consisting of large buoyant particles, and pattern B consisting of 
small dense particles.  Under a similar separation principle to GGE, TGE permits 
separation of LDL into seven subfractions in a time span of sixty minutes, making it 
much more practical in a clinical setting.72  Compared to slab gels, tube gels are 
advantageous because lateral movement of proteins is less prone to occur, thereby 
improving resolution.   
      The VAP method, utilized by Atherotech, is a centrifugation technique that 
employs dense solutions of KBr to isolate the various lipoprotein fractions followed by a 
scan of the absorbance of the solution over the length of the tube.73, 74  This typically 
entails puncturing the bottom of the centrifuge tube using a continuous-flow chemistry 
analyzer to monitor the sample as it elutes.  This method has allowed for the analysis of 
five subclasses of LDL as well as two subclasses of HDL and is similar to the DGU 
methods reported by Hosken and Johnson.3, 4  The key differences are that the VAP 
method utilizes KBr salts as opposed to salts of heavy metal EDTA complexes and 
measures components based on UV absorbance instead of fluorescence.  The VAP 
method also yields a crude separation of the lipoprotein classes, whereas the DGU 
method relies on the equilibration of lipoprotein particles as the gradient forms during a 
spin.  The VAP method also utilizes a vertical orientation in the rotor as opposed to a 
fixed angle or swinging bucket configuration.  A further disadvantage of this method is 
that some lipoprotein material may irrecoverably adhere to the sides of the elution 
tubing.   
      As an alternative to separatory techniques of analysis, NMR provides a 
spectroscopic means of both quantifying lipoprotein particles and also giving 
information regarding their respective sizes.75, 76  This technique benefits from not 
requiring a pre-separation of the complex mixture of lipoprotein particles for analysis 
thereby offering a short analysis time, and has reportedly yielded results in good 
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agreement with both GGE and DGU.  The basic concept involves three steps: 
measurement of the plasma NMR spectrum, computer deconvolution, and calculation of 
concentration.  In particular, the methyl groups associated with the different types of 
lipid particles: phospholipids, cholesterol, cholesteryl esters, and triglycerides are 
measured.  Though it is not possible to distinguish between the methyl groups between 
these particles, the intensity of the bulk signal allows a quantification of the 
concentration of the sample, while the size of the particles affects the frequency and 
shape of the signal.77   
      To date, the most widely cited and used method of measuring cholesterol has 
been the Friedewald method, dating back over three decades.78  This method involves 
measuring the total cholesterol and total triglycerides by enzymatic methods, and 
measuring HDL cholesterol by rapid precipitation, then estimating the LDL cholesterol. 
(Eq. 1) 
 
5
LDL Plasma HDL
TGC C C= − −         (1) 
 
Though this has been a useful approximation, a direct measurement of the LDL 
cholesterol is a more desirable method of analysis. 
 
1.4 Density Gradient Ultracentrifugation  
      The lipid component of lipoprotein particles gives them a density that is 
substantially less than other constituents of plasma, allowing them to be isolated by 
ultracentrifugation (UC).17  Traditionally, there are two primary techniques employed for 
lipoprotein separation: rate zonal UC and isopycnic UC.  In rate zonal UC experiments, 
samples are layered beneath a preformed gradient comprised of different zones of 
particles of given flotation rates.  When centrifugal force is applied, the sample particles 
float through the gradient in separate zones, and the experiment is stopped before these 
zones migrate to the top of the UC tube.  Particles are therefore separated based on 
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which zone they migrate into.  In isopycnic separations, the density gradient covers the 
entire range of densities expected in the sample to be measured.  When centrifugal force 
is applied in this case, sample particles will migrate to the position in the tube at which 
its own density corresponds to the density of the gradient-forming solution, also known 
as the particle’s isopycnic point.  Particles in this case are separated based solely on 
differences in their respective densities.  Though the isopycnic point of a particle is a 
fixed property of the molecule being studied, its relative position in a UC tube during an 
experiment can be modified by adjusting the density gradient-forming solute.     
 
1.4.1 Sedimentation Theory 
As a DGU experiment is being performed, there are two competitive forces that 
result in an equilibrium gradient solution: sedimentation and diffusion (buoyancy).  If a 
particle with mass, m,  is subject to a centrifugal field caused by a spinning rotor with 
angular velocity, ω, and radius, r, the particle will experience a centrifugal force as seen 
in the following formula: (Eq. 2)79 
 
2
centrifF m rω=          (2) 
 
Displacement of solvent particles will occur as the solute particles are placed in 
motion, and will have a resistance to this displacement, otherwise known as the buoyant 
force (ν).  This force will reduce the net force on the solute particles by a factor of (ω2r) 
times the mass of the solvent being displaced.  Since mass can be determined by 
multiplying the density (ρ) of a solution by its volume, written as mass (m) times the 
partial specific volume (υ ), the resulting buoyant force is given by: (Eq. 3)79 
 
2
buoyantF rmω υρ=          (3) 
  
The frictional force between the solvent and solute particles must also be 
accounted for since it opposes the motion of both the centrifugal and buoyant forces.  
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The frictional coefficient (f) is a function of the velocity (υ) of the moving particles, but 
when the net force on the particles is zero, as is seen in the case of equilibrium, the 
velocity of the particles is constant and the equation becomes: (Eq. 4)79: 
 
2 (1 )m
f
ω υρυ −=          (4) 
 
Equation 4 explains several key points about sedimentation theory.  Massive particles, as 
well as dense particles, tend to move faster than smaller or more buoyant particles.  
Also, denser solutions will cause the particles to move more slowly due to a higher 
frictional coefficient between solute and solvent, thereby causing the particles to move 
more slowly as well. 
 When a gradient-forming solute system is spun in a DGU experiment beginning 
from a homogeneous solution, the density of the solution will increase exponentially as 
the solution depth proceeds away from the meniscus. (Eq. 5)  In other words, the 
meniscus of the solution will have a low tube coordinate and the bottom of the UC tube 
will have a high tube coordinate.  This density versus tube coordinate relationship can be 
fitted to an exponential curve function and will typically range from 1.00 g/mL, the 
density of pure water, to as high as approximately 1.40 g/mL.  
 
( )
0
x
BAe yρ = +          (5) 
 
In this equation the density, ρ, is calculated as a function of the UC tube length, x, with 
coefficients A, B, and intercept y0.  By creating a calibration curve linking refractive 
index with the density of these solutions, the slope of the density curves can be obtained 
by spinning a solution of the desired density gradient-forming solute and measuring the 
refractive index as a function of tube depth.  The resulting density curve is useful in 
equilibrium isopycnic DGU experiments because it becomes possible to determine the 
density of the components of a sample based on their position in the UC tube. 
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 During a DGU experiment, it is seen that the molecular weight (M) of gradient-
forming solute systems is an important factor in determining the slope of the density 
curve, resulting in various degrees of separation of components in a mixture.4  The 
relationship between the molecular weight of the gradient-forming solute and the slope 
of the density curve can be derived by using the free energy concept. At equilibrium the 
concentration of molecules are not equal throughout the solution though the free energy 
must be the same throughout the solution.  This means that free energy (ΔGcentrif) 
decreases as work is done by centrifugal force to move a molecule of mass  
(corrected for buoyancy of the solute) from point r
m′
1 to point r2 as given by the following: 
(Eq. 6)79 
 
2
1
2
2
2 2
2 1( )2
r
centrif r
G m r d
m r r
ω
ω
′Δ = −
′= − −
∫ r
        (6) 
 
The variable m is equivalent to the term m(′ 1 υρ− ), which, when substituted into Eq. 6 
becomes: (Eq. 7)79 
 
2 2 21
2 12 (1 ) ( )centrifG m rυρ ωΔ = − − r        (7) 
 
The free energy change is not zero, but does move in the direction of the centrifugal field 
and is balanced by the force of diffusion.  This means that as a molecule moves from a 
coordinate of r1 at a concentration of c1 to a coordinate of r2 with a concentration of c2, 
the free energy change (ΔGdiff) is seen as: (Eq. 8)79 
 
2 1ln( )diffG kT c cΔ =         (8) 
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At equilibrium, ΔGcentrif is equal to ΔGdiff, therefore Eq. 7 and Eq. 8 can be reduced to: 
(Eq. 9)79 
 
2 1
2 2 2
2 1
ln( )(2 )
(1 ) ( )
c c kTm
r rυρ ω= − −         (9) 
  
Since m is in grams, the molecular weight can be determined by multiplying by 
Avogadro’s number ( ), and since k = R, Eq. 9 becomes: (Eq. 10)Ν Ν 79, 80 
 
2 1
2 2 2
2 1
ln( )(2 )
(1 ) ( )
c c RTM
r rυρ ω= − −         (10) 
 
1.4.2 Solute Systems 
Common solute systems for the separation of lipoprotein particles in DGU 
include KBr,81, 82 CsCl,83 and sucrose.84  These also exists less common, non-ionic solute 
systems such as the iodinated Nycodenz85 and Iodixanol.86  The evolution of these 
various solute systems over time has steadily led to better separations of lipoprotein 
particles. 
Alkali halide salts such as KBr and CsCl require a discontinuous gradient system 
that is labor intensive to prepare and is more suitable for sequential flotation 
experiments.  Since they require high salt concentrations, they also result in final 
solutions that have a high ionic strength.  This can be detrimental to lipoprotein analysis 
because high salt concentration can potentially disrupt the hydrophobic domains of 
proteins, thereby affecting their native structure. 
The non-ionic gradient-forming solutes circumvent the ionic strength problem, 
while still offering the ability to successfully separate lipoprotein particles.  Sucrose has 
traditionally been utilized in such experiments due to its high solubility and low cost.  
However, sucrose is so viscous that DGU experiments are typically limited to rate-zonal 
spins.  Furthermore, sucrose also interacts so strongly with lipoprotein particles that it 
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can be difficult to fully remove from lipoprotein samples.  This poses considerable 
problems when attempting to study the intact structure of lipoprotein particles since the 
sucrose can affect their native state.  Nycodenz and Iodixanol are two other non-ionic 
self-generating gradients that allows for a much shorter analysis time than the alkali 
halide salt methods.  Due to the iodization found in their structures, they are a 
considerably higher molecular weight than sucrose, which allows them to form a density 
gradient more quickly.  They also can be removed relatively easy from samples 
following a centrifugation experiment, making them useful for preparative work.  
 
1.4.3 Fluorometric Imaging of Lipoproteins 
Prior to DGU analysis, lipoprotein molecules are fluorescently labeled by a 
lipophilic molecule known as NBD (C6-ceramide) (Figure 2).3, 4, 10   
 
 
Figure 2.  Structure of NBD (C6-ceramide) 
 
This fluorophore consists of a hydrophilic head and a hydrophobic tail and only 
fluoresces when the fluorescent head is incorporated into a hydrophobic environment, 
such as the lipid core of a lipoprotein particle.  When it is in a favorable environment, 
the NBD-lipoprotein complex will exhibit characteristic excitation and emission spectra 
(Figure 3).  Once the serum sample is incubated with this molecule, it is analyzed by 
DGU.  Upon completion of the spin, the fluorescence of the NBD-lipoprotein complex 
allows for the generation of a lipoprotein density profile that enables a visualization of 
the distribution of lipoprotein particles.   
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Figure 3.  Excitation and Emission Spectra of NBD (C6-ceramide) 
 
1.4.4 Statistical Analysis 
The utilization of NBD (C6-ceramide) as a lipophilic stain for lipoprotein density 
profiling can be useful in generating data to describe the distribution of lipoproteins in a 
patient sample as a function of density and abundance.  In addition, this data can be used 
to classify cardiovascular risk in subjects by way of modern statistical methods.87  These 
statistical methods can be used to rank lipoprotein subclasses according to how strongly 
they influence this classification.  One study utilized high performance liquid 
chromatography (HPLC) to study lipoprotein particle size as the defining parameter.87  
To classify two groups as belonging to a control group or at risk for developing CAD, a 
method of analysis known as linear discriminate analysis (LDA) can be applied.88, 89  
This method attempts to find a linear combination of variables that can best separate the 
two groups in terms of the mean of their linear combination.  Newer statistical methods 
include sliced average variance estimation (SAVE)90, 91 and sliced mean variance 
covariance (SMVCIR).  These two approaches search for linear combinations of 
variables which yield the best separation of the two groups based on the mean, variance, 
and covariance of these linear combinations.  It was shown that classification can 
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typically be greatly improved by including both the variance and covariance in addition 
to the mean.90, 91  The combination of these statistical methods, results in a strong 
classification system that can be useful in screening samples prior to secondary analysis. 
 
1.5 Mass Spectrometry 
Methods of analyzing lipoproteins by mass spectrometry have become highly 
desirable due to the richness of information acquired in the data, the sensitivity of the 
technique, and the diversity in the types of mass spectral analysis that can be 
performed.92-95  In particular, techniques employing matrix-assisted laser desorption 
ionization (MALDI) and electrospray ionization (ESI) have run a large portion of the 
gamut over the past decade because the softer method of ionization possesses a lower 
risk of fragmenting the ions of interest. 
The goal of utilizing mass spectrometry in this study is to assist in generating a 
link between the composition of lipoprotein particles and the inherent risk of developing 
cardiovascular disease.  In particular, the lipoprotein HDL when observed at any point in 
its biological cycle will typically contain a mixture of apolipoproteins of various 
molecular weights ranging from approximately 6-30 kDa.  Even more interesting is that 
in a given serum sample, different HDL molecules may possess different quantities of 
these apolipoproteins, or even contain apolipoproteins that have undergone post-
translational modification.    
 
1.5.1 MALDI-MS 
In the late 1980’s, a novel ionization method known as MALDI mass 
spectrometry (MALDI-MS) was introduced that quickly became widely used in 
biological applications.96  It was discovered that by mixing a biological sample with an 
organic matrix, that non-volatile analytes could be desorbed by the use of an ultraviolet 
laser resulting in a plume of desorbed matrix and analyte ions, otherwise known as the 
MALDI plume.97  This phenomenon results in a soft-ionization of the biological sample 
which minimizes fractionation of large macromolecules and results primarily in a 
 19
mixture of singly and doubly charged intact molecular ions as well as some dimers.96, 98, 
99  Though it is still not currently fully understood how the ionization mechanism works, 
it is thought that the high UV absorbance of the matrix transfers energy to the analyte for 
ion formation.96, 100 
It is very common to couple a time of flight (TOF) mass analyzer to a MALDI 
ionization source, generating the analytical technique known as MALDI-TOF.101  In a 
typical MALDI-TOF experiment, analyte ions are accelerated by applying a fixed 
potential, known as the extraction potential, giving them a kinetic energy that is 
proportional to their mass-to-charge (m/z) ratio.  The accelerated ions then progress 
through a flight tube until they impinge on a detector plate which produces a signal for 
the ions as a function of time.  Since the time it takes the ions to reach the detector is a 
function of their kinetic energy, which is related to their m/z, a mass spectrum can be 
generated.  This means that molecular ions with a higher m/z will achieve a slower final 
velocity than ions with a low m/z.   
The resolution the instrument is capable of depends on factors such as the spatial 
orientation of molecules as they desorb from the matrix, the kinetic energy of the 
molecules, and the time required for acceleration of the analyte ions.102  In other words, 
this depends on whether all of the molecules start at the same position and are 
accelerated towards the detector uniformly. There are two methods that can be utilized 
combat these setbacks: delayed extraction103, 104, or use of a reflectron105. Delayed 
extraction involves delaying the extraction potential by a finite amount of time after the 
ionization event occurs as opposed to leaving the potential on continuously.  This serves 
to prevent molecular ions that are quickly formed from being instantly accelerated 
towards the detector.  As the MALDI plume forms, ions that are closer to the source of 
the extraction potential will experience less of an accelerating force as those that are 
further away because they will be exposed to it for a shorter duration of time.  This 
method normalizes the initial momentum of molecular ions at the beginning of the 
experiment and helps to provide a higher mass resolution.106  A reflectron, on the other 
hand, takes into account differences in kinetic energy and involves applying a fixed 
 20
potential gradient at a 180º angle to the direction of ion motion at a position where the 
detector would typically be placed in a linear TOF experiment.  Ions with a higher 
kinetic energy will penetrate deeper into this potential gradient and will take longer to 
turn around than ions with lower kinetic energy.  This adaptation to the TOF experiment 
has the advantage of refocusing the molecular ions, but also to give a flight path that is 
twice as long as an experiment performed in the linear mode.    
Careful consideration must also be taken in the choice of the MALDI matrix to 
be used.107  Common matrices include: sinapinic acid, ferulic acid, 2,5-
dihydroxybenzoic acid (DHB), and α-cyano-4-hydroxycinnamic acid (CHCA).108, 109  
Typically, the matrix compound must absorb the laser radiation strongly and must also 
be soluble enough in the sample solvent to be present in excess relative to the sample 
analyte.108  Additionally, the macromolecule being studied should not absorb the laser 
radiation to prevent fragmentation of the molecular ion.  There are typically two 
methods for preparing a sample for MALDI analysis:  the dried-droplet method96 and the 
thin-layer110 method.  The dried-droplet method consists of mixing the analyte with the 
desired matrix, then applying a small volume to a MALDI plate and allowing crystals to 
form through evaporation.  The thin-layer method involves first creating a layer of 
matrix only crystals, and then subsequently layering the matrix/sample mixture on the 
previous layer.  The thin-layer method has become advantageous because it leads to 
more homogeneous spotting of sample analyte, while the dried-droplet method tends to 
lead to heterogeneous “hot spots”.  Additionally, the thin-layer method allows for 
washing of the dried spot with deionized water for removal of contaminants that would 
otherwise be trapped in the crystallized matrix.   
The characterization of proteins and apolipoproteins by MALDI-TOF has been 
very successful over the past two decades, and has allowed for high mass accuracy of 
intact proteins and even identification of post-translational modifications.100, 111  The 
technique is not without its faults however.  Differences in ionization efficiencies of 
components of a mixture make quantification by MALDI difficult.  This is further 
compounded by mass discrimination and suppression effects as well as possible 
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fragmentation of the molecular ions during ionization.  Despite these setbacks, MALDI-
TOF still remains a rugged and robust method for analyzing macromolecules. 
 
1.5.2 LC-MS 
By combining the physical separation capabilities of liquid chromatography with 
the mass analysis capabilities afforded by mass spectrometry, the analytical technique of 
liquid chromatography mass spectrometry (LC-MS) has evolved as a powerful method 
of analyzing complex mixtures.  Akin to the technique of high performance liquid 
chromatography (HPLC), LC-MS functions on the same chromatographic principles, 
except on a much smaller scale, with typical column diameters of 4.6 mm for HPLC and 
300 µm for LC-MS.  For protein analysis, the liquid chromatography experiment is 
typically performed in the reversed phase by means of a hydrophobic c-4 or c-18 column 
and elution in a polar mobile phase consisting of a mixture of buffer and polar organic 
solvents.  The most common detection systems for LC-MS include: atmospheric 
pressure chemical ionization (APCI), thermospray, and also electrospray ionization 
(ESI).108, 112  Off-line MALDI deposition has even been used as a means of combining a 
liquid separation method with a gas phase ionization method.113, 114   
APCI is a form of chemical ionization that takes place at atmospheric pressure.  
Ions are produced when the analyte collides with ions of a reagent gas that have been 
exposed to electrons in the ion source.  The primary ions formed from the collision of 
electrons and the reagent gas will in turn collide with either other reagent gas molecules 
or analyte molecules.  The possible combinations include: protonation, proton 
abstraction, adduct formation, or charge exchange, leading to a host of different product 
ions.115  Thermospray is an adaptation of APCI in which the total effluent from a column 
is vaporized in a stainless steel capillary tube, forming an aerosol of solvent and analyte 
molecules  This aerosol is then ionized through a charge exchange mechanism with a 
salt that is incorporated into the eluent.116  In this manner, thermospray serves as both an 
interface to liquid chromatography and also as an ionization source.115  However, the 
thermospray interface can only be applied to polar analyte molecules and the mobile 
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phase used in the liquid chromatography portion must be capable of dissolving the salt 
responsible for the charge exchange step.   
Interfacing a liquid phase technique, which continuously flows liquid, and a gas 
phase technique carried out in a vacuum was still difficult for a long time, but the advent 
of ESI changed this.  Electrospray ionization mass spectrometry (ESI-MS) was first 
described in 1984 and has become one of the most important analytical techniques for 
analyzing biomolecules with molecular weights above 100,000 Da.117  This technique 
involves an ionization process that is extremely soft and results in little fragmentation of 
large and thermally fragile biomolecules.108  The method of ionization involves pushing 
a solution of analyte dissolved in a volatile solvent, usually containing an acid or a base, 
through a small diameter capillary that is charged.  Upon exiting the capillary the analyte 
particles will retain their charge state and will repel each other when a voltage is applied 
due to coulombic forces.  As the potential is increased up to a point known as the 
threshold voltage, the coulombic repulsive force of the analytes will begin to overcome 
the surface tension holding them together in solution, forming what is known as a Taylor 
cone.118  Two competing theories exist that explain how lone analyte ions are generated 
from the Taylor cone: the charged residue model (CRM), and the ion evaporation model 
(IEM).119  In the CRM, the electrospray droplets undergo evaporation and disintegration 
cycles in which coulombic repulsion reaches a critical level and explodes, causing the 
droplet to form progressively smaller daughter droplets which contain on average one or 
less analyte molecules.  The IEM however, suggests that as evaporation occurs, the field 
strength at the surface of the droplet becomes great enough to desorb lone analyte ions 
directly out of the droplet.  It is thought that both models probably occur depending on 
the analyte/solvent system being studied.  In either case, ESI serves to transfer analyte 
ions from a liquid to a gaseous state for entry into the mass analyzer. 
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1.6 Capillary Electrophoresis 
Lipoprotein subclasses are largely considered to have heterogeneous physical 
properties such as composition, size, hydrated density, and even apolipoprotein 
composition.120  As an example, all LDL molecules, regardless of density, should 
possess the apolipoprotein B-100.  Similarly, all HDL molecules should possess the 
lipoprotein A-1.  However, since HDL molecules possessing the same physical 
properties can also contain a host of other apolipoproteins in addition to A-1, it becomes 
important to utilize other techniques capable of separating them.  One such technique is 
CE, which has evolved as a powerful separation technique for the study of these 
biomolecules.10, 11 
 
1.6.1 Separation Theory 
The main principle of CE involves the separation of components in a mixture 
based on their size-to-charge ratio when an electric field is applied to a capillary 
containing a conductive buffer, also known as the background electrolyte (BGE).121  
Smaller, more highly-charged species will be influenced by the electric field more, and 
will therefore have a higher rate of migration than molecules that have a lower size-to-
charge ratio.  This phenomenon is known as electrophoresis.  In addition to 
electrophoresis, there is another force known as electroosmosis that occurs as a result of 
the interaction between the charge of the surface of the capillary wall and the BGE when 
an electric field is applied.  A typical uncoated capillary wall is covered with 
deprotonated silanol groups, giving the capillary wall a net negative charge.  As the pH 
of the BGE increases, the degree of deprotonation also increases.  Cations from the BGE 
are attracted to the negatively charged capillary wall, forming an immobile wall of 
positive charge near the wall, known as the Stern layer.  Beyond the Stern layer, a 
diffuse layer of mobile cations, known as the Helmholtz plane, also forms.  Together, 
these layers are known as the electrical double layer.  When a potential is applied to the 
capillary, the diffuse layer of cations migrates toward the cathode, dragging its hydrated 
layer of water molecules with it in a bulk flow known as the electroosmotic flow (EOF).   
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 In CE, the measure of the rate of migration of molecules is known as the mobility 
(μ), and is a function of the total capillary length in cm (Lc), length to the detector in cm 
(Ld), the applied voltage in volts (V), and time for an ion to reach the detector in seconds 
(t). (Eq. 11) 
 
c dL L
V t
μ ×= ×           (11) 
 
The apparent mobility of the analyte of interest (μapp) is the sum of the effective mobility 
of the analyte (μeff) and the mobility of the EOF (μEOF). (Eq. 12). 
 
app eff EOFμ μ μ= +          (12) 
 
The apparent mobility for the analyte of interest is found by calculating the mobility, as 
given by Eq. 11, with the time it takes for it to reach the detector.  The mobility of the 
EOF is calculated in the same manner, but by using the time required for a neutral 
marker to reach the detector (tEOF).  By calculating these two mobilities, it becomes 
possible to solve for the effective mobility of the analyte of interest.  Another way to 
express this is by combining Eq. 11 and Eq. 12 and solving in terms of the effective 
mobility. (Eq. 13) 
 
1 1c d
eff
EOF
L L
V t t
μ ⎛ ⎞×= × −⎜⎝ ⎠⎟         (13) 
 
    The choice of polarity also influences the separation.  Under normal polarity, in 
which the anode is located at the inlet and the cathode is located at the outlet, the EOF 
will travel towards the detector.  As a result, the mobility of the EOF versus the mobility 
of the analytes to be studied becomes important.  If the analyte molecule is an anion, it 
must have a lower mobility than the EOF so that it can essentially be pulled to the 
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detector by the bulk flow; otherwise it will simply migrate to the anode and will never be 
detected.  When analyzing biomolecules by CE, the pH of the BGE becomes important 
because it will dictate both the mobility of the EOF as well as the charge of the analyte 
molecule.  Therefore, for protein studies, a pH above the pI of the protein will yield an 
anionic analyte ion, whereas a pH below the pI will yield a cationic analyte ion.   
 Electromigration dispersion (EMD) can also cause considerable distortions of 
peak shape that will affect the separation efficiency.122-124  This phenomenon is 
characterized by peak tailing or fronting, and occurs as a result of a difference in 
mobilities between the buffer ions and sample ions in a given separation experiment.  
Through careful selection of BGE to match the mobility of buffer ions with the mobility 
of sample ions, this deleterious effect can be minimized.  
It is also important to note that significant analyte/wall interactions can occur 
when the net charge of the biomolecules is opposite to that of the capillary wall, thereby 
hindering the separation.  Methods of solving this include: using a high pH BGE to 
minimize protein adsorption through coulombic repulsion, adding surfactants to the 
buffer to dynamically coat the capillary wall, or shielding the capillary wall by coating it 
with a neutral hydrophilic compound.125-127  The addition of surfactants may also serve a 
role in denaturing proteins, which can serve to alter their hydrodynamic volume, thereby 
causing deviations in mobility from their native structure.  Furthermore, modifications to 
the BGE that include adding charged surfactants can change the surface charge of 
proteins which can also affect their mobility.  For example, the addition of the anionic 
detergent sodium dodecyl sulfate (SDS) will cause a significant increase in the charge of 
the protein to be analyzed, therefore increasing its electrophoretic mobility.128  SDS also 
has the added benefit of reducing protein-protein interactions and helps to eliminate 
aggregation of biomolecules.129   
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1.7 Isoelectric Focusing with an Immobilized pH Gradient 
Immobilized pH Gradients (IPG) were developed in the early 1980’s to 
overcome setbacks with existing IEF methods.13  In this technique, ampholytic 
molecules are immobilized by chemical bonds to a gel matrix composed of 
polyacrylamide, forming a continuous pH gradient.  Typically these molecules are 
derivatives of acrylamide of the form:  CH2=CH-CO-NH-R, where R can be either a 
carboxyl group or a tertiary amino group.14  When a protein sample is loaded onto the 
gel, the protein will be charged relative to the environment it is in and will migrate under 
the influence of an applied electric field.  Migration of the protein will stop once the 
protein migrates to a region of the IPG gel in which the pH matches the pI of the protein.  
This indicates that the protein will have a neutral charge and its mobility will be zero.  In 
this manner, a complex mixture of macromolecules can be separated if the various 
components possess unique pI values, with a resolution as high as ΔpI = 0.001.14  An 
equation for the resolving power of IEF can be expressed as a function of electrical and 
diffusional mass transport. (Eq. 14)14 
 
3
[ ( ) / ]
[ / ( )
D d pH dxpI
]E du d pH
Δ = −         (14) 
 
In this equation, D is the protein diffusion coefficient at the pI, d(pH)/dx describes the 
slope of the pH gradient of the IPG gel, E is the electric field strength, du/d(pH) is the 
mobility gradient of the analyte at the pI, and ΔpI is the difference in pI between 
analytes.  This equation demonstrates that the highest resolution can be obtained when 
the analyte has a low diffusion coefficient and a high mobility slope.  Since proteins 
have high molecular weights with low charge states, this condition is met.  Shallow pH 
gradients and high electric field strengths also contribute to higher resolutions.     
Experimental pI values can be predicted for proteins by examining amino acids 
that contain residues capable of ionization.130  However, ampholytes in the IPG gel are 
sensitive to temperature, urea concentration, and presence of detergents, all of which can 
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alter their pI values.  Urea is typically used as a chaotropic agent to disrupt hydrogen 
bonding in a protein, essentially eliminating secondary and tertiary structures, and 
resulting in a protein with only primary structure.131, 132  Detergents are used to bind to 
non-polar domains of a protein in order to reduce hydrophobic interactions.133, 134  While 
the presence of urea and detergents are helpful in IEF separations, the presence of salts 
are detrimental.  Salt contamination can deplete water from the gel prior to protein entry, 
and can allow for precipitation of proteins from solution, or slow migration of the 
protein in the gel.135  Protein identification can be accomplished by either comparing 
predicted pI values with experimental values, or through the use of reference 
standards.130  Other advantages include:  sharp protein bands, high reproducibility, and 
low background staining.  The method however is capped at a maximum mass limit on 
the order of 750,000 Da. 
 
1.8 Application of Methods 
Ultimately, the goal of this research is to generate information-rich methods for 
analyzing clinical samples to determine a patient’s risk of developing CAD.  Since the 
information acquired from many of these methods overlaps, it becomes possible to 
investigate many aspects of an individual’s lipoprotein composition to give an improved 
overview of their CAD risk assessment.  With this goal in mind, the term lipoproteomics 
was coined by our research laboratory to describe the combination of techniques utilized 
to paint the picture of an individual’s cardiovascular risk profile.  Traditionally, the 
predominant risk factors associated with CAD risk have focused on the concentrations of 
LDL cholesterol (LDL-C) and HDL cholesterol (HDL-C).  Specifically, people with 
elevated levels of LDL-C are at greater risk for developing CAD and are deemed pro-
atherogenic, while those with elevated HDL-C are deemed anti-atherogenic.136  
However, cholesterol levels are only a small piece of a much larger puzzle, and 
investigations into the protein content of lipoproteins will aid in unveiling the direction 
in which cardiovascular research should progress.  The largest bottleneck in proteomics 
has been identification.  Relatively high amounts of protein are required, and 
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cumbersome sequencing techniques greatly limits throughput.137  Although two-
dimensional polyacrylamide gel electrophoresis (2D-PAGE) coupled with mass 
spectrometry has long been the go-to method for identification of new proteins, the 
throughput simply is not high enough.  The research described here presents an approach 
in combining various analytical techniques in order to not only more thoroughly analyze 
the complex distribution of apolipoproteins present in a sample of human serum, but to 
help increase sample throughput as well. 
MALDI-MS has been widely used for the characterization of complex protein 
mixtures because it yields many singly-charged ions with high mass accuracy, making 
individual protein identification possible.100, 111  Post-translational modifications such as 
glycosylation, phosphorylation, and acetylation can also easily be detected.94, 95 MALDI-
MS experiments following an isolation of lipoprotein types by DGU has allowed for 
considerably more selective examination of subclasses of major lipoprotein types.  
Mixtures of apolipoproteins, particularly those from different fractions of HDL, have 
been analyzed and multiple isoforms have been reported.138-141  Novel isoforms of the 
inflammatory response protein, serum amyloid A (SAA), have also been successfully 
analyzed by DGU-MALDI experiments.142  Fractions of VLDL have also been analyzed 
in this fashion, and novel isoforms of apo C-III were detected as well as different 
polymorphisms of the apolipoproteins.139, 143  Several cases of suspected methionine 
residue oxidation have also been detected in the apolipoproteins of both VLDL and 
HDL.139, 144-147  MALDI-MS can serve as an invaluable qualitative analysis tool with a 
very high sensitivity, but it is not typically used in experiments requiring quantitation. 
LC-MS is advantageous over MALDI because of its ability to separate complex 
mixtures prior to mass spectrometric analysis, thereby enabling researchers to study 
complex mixtures of the lipids or proteins associated with lipoprotein particles.  It has 
been particularly useful in the qualitative and quantitative analysis of lipid and 
phospholipid content of human lipoproteins, especially HDL.148-151  This technique has 
even been utilized in studies aimed at tracking the hydrolytic activity of various 
phospholipases towards phosphatidylcholine contained in human LDL and HDL.152  For 
 29
nutritional studies, LC-MS has also been useful in identifying and quantifying 
circulating phenolic compounds and their metabolites.153, 154  These compounds can be 
obtained from meals containing olive oil or red wine and are considered to act as in vivo 
antioxidants.  In regards to protein analysis, LC-MS has been useful in determining post-
translational modifications of single proteins, as is the case when analyzing the oxidation 
of apoB-100 in samples of human LDL.155 It has also been used considerably in studies 
aimed at identifying and quantifying the apolipoproteins of VLDL, LDL, and HDL.156, 
157  While these experiments report the absolute quantities of the various apolipoproteins 
studied, tryptic digestion is required, thereby eliminating the nascent structure of the 
proteins.  The results reported in this dissertation describe methods to begin filling in this 
vital missing information. 
Considerable efforts are being made to push CE towards more commercial use to 
be utilized alongside techniques such as high performance liquid chromatography 
(HPLC), mass spectrometry and gel electrophoresis.158 Electrophoretic methods that 
have been utilized to study lipoprotein particles for the last two decades include 
techniques such as capillary isotachophoresis (CITP)159, capillary zone electrophoresis 
(CZE)160, capillary sds gel electrophoresis161, and microchip CE11.  In its simplest form, 
CZE involves analyzing a heterogeneous mixture of samples in a low viscosity buffer 
which is subjected to an electric field, with separation occurring as a result of differences 
in mobility.162  Additional advantages include the relatively low sample volume required 
for the measurement, as well as higher sample throughput.  For lipoprotein analysis, CE 
experiments exist in two primary branches:  intact lipoprotein analysis, and delipidated 
analysis of apolipoproteins.  Lipoprotein particles in their nascent state are negatively 
charged when at physiological pH.  In studies involving intact lipoproteins, a slightly 
basic buffer is typically utilized to ensure that lipoprotein molecules will remain near 
their physiological pH and ensure their negative charge.  In this manner, information 
regarding the size/charge of the lipoprotein particles can be acquired.  This information 
can be used to help determine the inherent differences between both the apolipoprotein 
content, and the lipid content in a variety of samples, particularly in oxidation studies.163  
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Oxidation can affect the size/charge of a lipoprotein particle, thereby affecting its 
electrophoretic mobility.  CITP experiments of intact LDL particles have been used to 
study its various subfractions.10, 159, 164-166 Since the primary apolipoprotein associated 
with LDL particles is apo B-100, it then becomes possible to look at changes to the lipid 
structure.  For the analysis of the apolipoproteins, the intact particles can be delipidated 
by various techniques, such as addition of detergent to the CE buffer, or solid phase 
extraction (SPE), prior to the electrophoresis experiment.12, 128  This provides a means of 
analyzing the apolipoproteins of LDL and HDL for quantitative purposes by CZE.12, 167  
The effective electrophoretic mobility of the various apolipoproteins allows a second 
degree of separation over DGU because molecules possessing different electrophoretic 
mobilities will travel at different rates. 
Experimental data from apolipoprotein studies also suggests that there are 
multiple isoforms of the major apolipoprotein classes.  The distribution and quantity of 
these isoforms could potentially yield information that would benefit the diagnosis of 
cardiovascular health.  Coupling immunoaffinity with traditional CE experiments has 
opened up a large avenue of possibilities for proteomics studies as well.137  
Immunoaffinity CE (IACE) experiments involve capturing an analyte of interest with an 
affinity ligand, washing non-specifically bound material, followed by elution of the 
desired analyte in a desorption buffer.  This would offer the researcher additional 
selectivity since the majority of apolipoproteins have very similar electrophoretic 
mobilities.   
IEF can be used as either a standalone method to analyze the distribution of pI 
values of a sample mixture or it can be used as a preparatory step for 2D-PAGE 
experiments.  Due to its high inherent resolution, IEF is a very suitable technique for 
resolving complex mixtures of apolipoproteins.  Several staining methods, including 
visible organic stains, fluorescent stains, and silver staining are available for imaging of 
proteins.14  Typically, colloidal solutions of the dyes in acidic solutions are utilized for 
proteins separated on an IPG strip in order to minimize background staining of the gel 
support.168  At low pH the protein molecules are protonated, giving nucleation centers 
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which are capable of binding molecules of the dye through electrostatic attraction while 
the gel support cannot be penetrated as well by the colloidal dye molecules.  Acid Violet 
17 was found to be a very reproducible stain for protein samples, with a sensitivity as 
low as 5-10 ng of protein per zone and a linear range of 1-100 ug.169  As the first 
dimension of a 2D-PAGE experiment, IEF has been used to identify several post-
translational modifications of human plasma apolipoproteins.170 IPG gels have also been 
useful in detecting differences in isoforms of Apo C contained in VLDL in studies 
involving hypertriglyceridemic indviduals.171  The phenotyping of apolipoprotein E from 
samples of VLDL and serum has been accomplished by combining IEF with 
immunodetection.172, 173  Isoforms of apolipoprotein A-I from HDL samples have also 
been separated by IPG gels and detected by a combination of staining with Coomassie 
Blue and immunoblotting.174, 175  Genetic polymorphisms have also been analyzed from 
a mixture of lipoprotein fractions that were analyzed through use of pre-cast IPG gels 
and stained by colloidal Acid Violet 17.169, 176, 177  Tryptic digest of protein spots from 
gels has also been utilized as a preparative step for analysis by MALDI-MS.178 
By working in conjunction with clinicians at Scott & White Hospital, we are 
developing a library of patients that do not possess traditional risk factors for 
development of CAD, yet have severe levels of atherosclerosis.  Our goal is to apply this 
array of methods to a sample population consisting of subjects with a known history of 
cardiovascular events and subjects considered to be at low risk for development of CAD. 
The final aim is the potential discovery of new risk factors to provide insight as to how 
and why CAD develops.  Combining DGU, both as a standalone analysis method and as 
a preparative tool, with techniques capable of secondary separation and analysis, such as 
MS, CE, and IEF, enables a much more focused ability to observe distributions of the 
subclasses of lipoproteins.  In addition, this combination of methods also yields 
important information regarding the quantity and distribution of apolipoproteins.  Pooled 
together, this information will become part of an ongoing effort to better understand 
features of lipoproteins, and how CAD develops.  The following table summarizes the 
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relative abundances, CE mobilities, mass averages, and pI values expected for the A and 
C apolipoproteins in a typical sample of HDL (Table 3).31, 143, 167, 179-181     
 
Table 3.  Summary of Apolipoprotein A and C Properties 
Apolipoprotein Serum Conc. (mg/dL) 
Mobility 
(x 10-5 cm2/Vs) Avg. Mass (m/z) pI 
A-I 100-150 -24.8 28,078.60 5.34 - 5.75 
A-II 30-40 -22.8 17,379.80 4.20 - 5.17 
C-I 6 -26.8 6,630.60 6.50 
C-II 4 -24.1 8,914.20 4.50 – 4.82 
C-III 12 -24.6 9,429.98 4.80 - 4.95 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 Chemicals and Supplies 
 NBD (C6-ceramide) was purchased from Molecular Probes (Eugene, OR).  
Sodium bismuth ethylenediaminetetraacetic acid (NaBiY) was purchased from TCI 
America (Portland, OR).  Cesium hydroxide, cesium carbonate, cadmium carbonate, 
ethylenediaminetetraacetic acid (H4EDTA), sodium carbonate, lead carbonate, disodium 
copper ethylenediaminetetraacetic acid (Na2CuY), sodium iron 
ethylenediaminetetracacetic acid (NaFeY), trichloroacetic acid, trifluoroacetic acid 
(TFA), ferulic acid, sinapinic acid, sodium borate, sodium dodecyl sulfate (SDS), 
Dextralip® 50, and magnesium chloride hexahydrate were purchased from Sigma 
Aldrich (St. Louis, MO).  Acetonitrile (ACN), dimethyl sulfoxide (DMSO), glycerol, 
phosphoric acid, and methanol were purchased from EM Science (Gibbstown, NJ).  
Bismuth oxycarbonate was purchased from Alfa Aeser Co. (Ward Hill, MA).  
Immobiline™ DryStrips and DeStreak™ rehydration solution were purchased from GE 
Healthcare (Piscataway, NJ).  Acid Violet 17 was purchased from Serva Electrophoresis 
(Heidelberg, Germany).  Strata C18-E solid phase extraction cartridges and syringe 
adapters caps were purchased from Phenomenex (Torrance, CA).  Fused-silica capillary 
columns were purchased from Polymicro Technologies (Phoenix, AZ).  ApoA-I and 
ApoC-I standards were purchased from Academy Biomedical (Houston, TX). 
 
2.1.2 Synthesis of EDTA Complexes 
 In all EDTA complexes that are synthesized, the term “Y” represents a molecule 
of “EDTA” when complexed with a metal ion.  Complexes of CsBiY, Na2PbY, Cs2PbY, 
Na2CdY, and Cs2CdY were synthesized by stoichiometric combination of H4EDTA, the 
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appropriate alkali carbonate or alkali hydroxide, and the appropriate heavy metal 
carbonate in 100mL of deionized water (DI H2O), followed by a 2-h reflux, yielding a 
clear solution. (Eq. 15) 
 
4 3 2( ) ( ) ( )2H EDTA X CO M Z X M EDTA H O l CO g+ + → + +? ? ?     (15) 
 
In this equation, the general scheme of the reaction involves combining the fully 
protonated variant of EDTA with the desired alkali metal (X) carbonate, and with 
various forms of a heavy metal (M) such as its carbonate, oxide, oxycarbonate, or 
hydroxide, designated as (Z).  For example, the synthesis of CsBiY would involve 
reacting EDTA with cesium carbonate and bismuth oxycarbonate. (Eq. 16) 
 
4 2 3 2 2 3 22 2 4H EDTA Cs CO Bi OCO CsBiEDTA H O l CO g+ + → + + 2( ) 2 ( )    (16) 
 
After reaction, the resulting solution was then titrated with the appropriate alkali 
hydroxide to a pH ranging from 6.75-7.25, then reconstituted to a final volume of 
100mL to account for evaporation during reflux.  As long as the stoichiometry of the 
reaction is preserved, it can be scaled to give a higher concentration or volume of the 
desired EDTA complex.   
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2.2 Analytical Methods 
2.2.1  Serum Collection 
 Serum samples were collected by a blood draw into a 9mL Vacutainer tube 
treated with a polymer gel and silica activator from Beckton Dickinson Systems 
(Franklin Lakes, NJ).  The serum was then separated from red blood cells by 
centrifugation at 3,200 rpm for 20 minutes at 4ºC, followed by aspiration of the 
supernatant into 500uL Eppendorf tubes for storage at -80ºC prior to analysis.  Informed 
consent was obtained from all donors. 
 
2.2.2  Calibration of EDTA Complexes 
 Stock 0.4000M solutions of the EDTA complexes of NaBiY, CsBiY, Na2PbY, 
Cs2PbY, Na2CdY, Cs2CdY, NaFeY, and Na2CuY were prepared, and were used to 
prepare subsequent dilutions down to a final concentration of 0.0133M.  Gravimetry and 
refractometry were used to determine the relationships between concentration, density, 
and refractive index for each of the eight EDTA complexes.  A calibrated 10mL glass 
pipet was utilized to gravimetrically determine the density of the solutions at each 
concentration.  The refractive index was measured at 20ºC using an Abbe 60/DR 
refractometer from Bellingham + Stanley (Lawrenceville, GA). 
 
2.2.3  Measurement of Gradient Formation
 Density gradients were formed in an Optima TLX UC with a TLA 120.2 fixed-
angle rotor and in 1.5mL thick-walled, polycarbonate UC tubes from Beckman-Coulter 
(Palo Alto, CA).  Tubes contained 1,000uL of the appropriate EDTA metal complex and 
were centrifuged at a rotor speed of 120,000 rpm for 6 hours at 5ºC.  When the 
experiment is performed with a TLA 120.2 fixed-angle rotor, this rotor speed 
corresponds to a relative centrifugal force of 510,000g.  Once centrifugation was 
complete, 20uL aliquots were removed from sequentially lower positions within the UC 
tube (determined by imaging the location of the pipette tip during each removal step).  
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The refractive index was measured from each of these aliquots and was compared to the 
position from which they were removed.  From this series of refractive indices, the 
relative densities can be calculated, thereby linking the tube coordinate with the density 
of the EDTA metal complex solution.  This was repeated for each of the eight solute 
systems and yielded unique density curves for each EDTA metal complex. 
 
2.2.4  Ultracentrifugation of Serum Samples 
 There are two modes of operation for UC experiments:  serum density profiling, 
and preparative UC.  For serum density profiling, 6uL of serum and 84uL of DI H2O 
were added to a 1100uL solution of the desired density gradient-forming solute, 
followed by addition of 10uL of a 1mg/mL solution of NBD (C6-ceramide) dissolved in 
DMSO.  From this mixture, a 1,000uL aliquot was added to a UC tube and spun 
according to the conditions described above.  Following the spin, 200uL of DI H2O was 
layered atop the solution to assist in separating the buoyant and dense TRL classes.   
 For preparative UC in studies involving VLDL or LDL, 50-200uL of serum was 
added to a 1100uL solution of a 0.3000M solution of Cs2CdY, followed by addition of 
10uL of a 1mg/mL solution of NBD (C6-ceramide) dissolved in DMSO.  From this 
mixture, a 1,000uL aliquot was added to a UC tube and spun according to the conditions 
described above.  Studies involving HDL were first subjected to treatment with dextran 
sulfate (DS) and magnesium chloride in order to precipitate out lipoproteins containing 
apoB such as VLDL, LDL, and Lp(a) as follows.182  The 50,000 MW variant of DS is 
commercially available as Dextralip® 50.  1.0g of DS was combined with 10.15g of the 
dried salt of magnesium chloride hexahydrate in 100mL of DI H2O.  The final solution 
should have a concentration of 10 g/L of DS and 0.5M magnesium chloride.  This 
working solution was added to a sample of serum at a volume of 10% of the serum 
volume.  For example, a 100uL sample of serum should have 10uL of this working 
reagent added.  This solution was mixed briefly by vortexing and left to stand at room 
temperature for 10 minutes.  Centrifugation in a tabletop centrifuge at 12,000g for 5 
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minutes was then performed to sediment out the apo-B containing particles.  The 
supernatant was then prepared for UC as previously described. 
 
2.2.5  Fluorescent Imaging Analysis 
 Following a UC experiment, an image of the UC tube was obtained and analyzed 
by using a digital color microscope camera, Microfire S99808, purchased from 
Optronics (Goleta, CA) with a Fiber-Lite MH100A Illuminator from Edmund Industrial 
Optics (Barrington, NJ).  The camera and light source were positioned orthogonally to 
each other on an optical bench to illuminate the sample.  Filters matching the excitation 
and emission properties of the fluorophore, NBD (C6-ceramide), were purchased from 
Schott Glass (Elmsford, NY).  The respective filters for excitation and emission were a 
blue-violet filter (BG-12) with a bandwidth centered about 407nm and a yellow filter 
(OG-515) with a bandwidth centered about 570nm.  Specific settings for the Microfire 
camera software included an exposure time of 15.8ms for serum density profiling and 
29.0ms for preparative UC.  A gain of 1.000 and a target intensity of 30% were also 
applied. 
 From the image capture of the UC tube, a density profile was generated as 
described by a published method.4  Using Origin 7.0 software, the image was first 
converted into grayscale intensity values as a function of pixels in two dimensions, then 
the grayscale intensity from a small strip of 10 pixels oriented in the center of the UC 
tube was averaged.  This average grayscale intensity was then plotted as a function of 
tube coordinate (0-34mm) to give the final lipoprotein density profile. 
 
2.2.6  Lipoprotein Fraction Collection 
Lipoprotein fractions were collected by using a novel freeze/slice method.  After 
preparative UC and imaging, the UC tubes were slowly frozen in liquid nitrogen.  This 
was accomplished by placing the UC tubes into a custom 10-slot holder and slowly 
lowering the holder into a Dewar of liquid nitrogen, causing the liquid in the tubes to 
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freeze from the bottom to the top.  In this manner, the expansion of water to ice can be 
accounted for by the following equation: (Eq. 17) 
 
10.405ls l
s
mm mmρρ= × −          (17) 
 
In this equation, mms corresponds to the tube coordinate in solid state, while mml 
corresponds to the tube coordinate in the liquid state, the state in which the image of the 
UC tube is captured.  The term ρl/ρs corresponds to the ratio of the density of water at its 
liquid state ρl to its density at its solid state ρs.  Since water is denser in its liquid state, 
this ratio gives a correction factor greater than unity and the equation can be simplified 
to: (Eq. 18) 
 
1.058 10.405s lmm mm= × −         (18) 
 
Also, 10.405mm was subtracted from the solid state tube coordinate to correct for the 
calibration of the micrometer/tube holder assembly that was used to dial in the correct 
cut points.  This micrometer/tube holder assembly contains a micrometer head that was 
used to dial in the desired cut point, which functions to advance the position of the UC 
tube relative to the location of the notch for the saw blade.  A Dremel® scroll saw 
(Racine, WI) was fitted with 0.25mm blades for the cutting of the tubes.  The 
freeze/slice method is depicted below (Figure 4). 
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Figure 4.  Freeze/Slice Method for Excising Lipoprotein Fractions 
 
2.2.6.1 Solid Phase Extraction 
After sample excision and thawing, apolipoproteins were separated from lipids 
by means of a solid-phase extraction (SPE) cartridge from Phenomenex, Strata C18-E 
(Torrance, CA).  Delipidation of samples was accomplished based on a published 
method.181 
 
1. The cartridge was conditioned dropwise with three 1mL rinses of 0.1% (v/v)  
TFA in ACN, allowing no air to enter the cartridge. 
   2. The cartridge was then conditioned dropwise with three 1mL rinses of 0.1% (v/v) 
TFA in DI H2O, allowing no air to enter the cartridge. 
   3. The sample to be delipidated was first mixed with an equivalent-volume of 0.1% 
(v/v) TFA in DI H2O, then slowly added to the cartridge, allowing no air to enter 
the cartridge. 
   4. The cartridge was washed with three 1mL rinses of  0.1% (v/v) TFA in DI H2O in 
order to remove salts and non-specifically bound apolipoproteins.  Air was then 
pushed through the cartridge to remove any remaining liquid. 
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   5. The apolipoproteins were then eluted in 100uL aliquots of 0.1% TFA in ACN.  The 
first four aliquots contained the majority of the apolipoproteins (verified by 
MALDI-MS) and were combined.   
 
Following the SPE procedure, the samples were evaporated to dryness through 
use of a SVC-100H Speed-Vac concentrator with a refrigerated condensation trap from 
Savant Instruments (Farmingdale, NY) which was connected to a 5KC36PN435AX 
vacuum pump from General Electric (Fort Wayne, IN).  Dried apolipoprotein fractions 
were then reconstituted in suitable solvents for the method of investigation:  0.1% TFA 
in DI H2O for MS experiments, buffer for CE experiments, DeStreak™ for IEF 
experiments, and DI H2O for cell culture studies. 
 
2.2.6.2 Bicinchoninic Acid Assay (BCA) 
 For the determination of total protein concentration, a BCA protein assay reagent 
kit from Pierce Biotechnology was used (Rockford, IL).  Standard working reagent for 
the kit was prepared as follows: (Eq. 19) 
  
(# # ) (# ) ( )WR Stds Unk Reps Vol per Sample= + × ×     (19) 
 
In this equation, the volume of the working reagent (WR) is calculated by multiplying 
the total number of standards and unknowns (#Stds + #Unk) by the number of replicate 
measurements (#Reps) desired and by the volume required per sample.  For typical 
analyses, 150uL of sample is required, so if there were 5 standards and 5 unknowns, and 
triplicate measurement was required, 4,500uL of working reagent would be required.  In 
order to prepare the working reagent, three reagents need to be mixed in the proper ratio 
(Eq. 20). 
 
: : 25:24:MA MB MC = 1        (20) 
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MA:  =  Sodium carbonate, sodium bicarbonate, and sodium tartarate in 0.2N NaOH 
MB:  =  4% (v/v) Bicinchoninic acid in water 
MC:  =  4% (v/v) Cupric sulfate pentahydrate in water 
 
Using the above example, if 4,500uL of working reagent are required, then the ratios 
would calculate to 2,250uL, 2,160uL, and 90uL of MA, MB, and MC respectively.  
Once the standard working reagent was properly prepared, 150uL was pipetted into 96 
well microtitre plates, followed by 150uL of the desired sample or standard to be 
analyzed.  The microtitre plate was then placed in an oven and incubated at 37ºC for 2 
hours, then cooled to room temperature for 10 minutes.  The absorbance was then 
recorded at 562nm on a μQuant spectrophotometer from Bio-Tek Instruments 
(Winooski, VT). 
 In the BCA test for total proteins, Cu+2 is reduced to Cu+1 when it interacts with 
protein in an alkaline environment, with the amount of reduction being proportional to 
the concentration of protein present.  In the second step of the reaction, the newly 
formed Cu+1 ions are chelated by two molecules of bicinchoninic acid (Figure 5).183  The 
BCA/Copper complex is water-soluble and exhibits a strong linear absorbance at 562nm. 
 
 
Figure 5.  Reaction of Bicinchoninic Acid with Protein 
 
2.2.6.3 MALDI-MS Analysis of Apolipoproteins 
A commercial, Voyager-DE STR, MALDI-TOF mass spectrometer equipped 
with a 2m flight tube from Applied Biosystems (Foster City, CA, USA) was used for the 
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analysis of proteins (Figure 6).184  MALDI matrices consisted of solutions of either 
sinapic acid or ferulic acid at a concentration of 15mg/mL dissolved in methanol.  
Apolipoprotein samples were prepared for MALDI analysis by de-salting and pre-
concentrating with a C4 ZipTip™ from Millipore (Billerica, MA).  Samples then 
underwent a thin-layer sample preparation method in which a MALDI plate is first 
spotted with the desired MALDI matrix and allowed to dry, and then a mixture of the 
sample and matrix is deposited atop the original spot.  Myoglobin was used as an 
external mass calibration standard.  For MALDI analysis, the acceleration potential was 
held at 25kV, the grid potential was at 93%, and delay time was 550ns. 
 
 
Figure 6.  Voyager-DE STR MALDI-TOF Mass Spectrometer 
 
2.2.6.4 LC-MS Analysis of Apolipoproteins 
 Dried protein samples were first reconstituted in 100uL of 0.1% TFA in DI H2O.  
HPLC was then performed using an Agilent 1200 Capillary Pump and Microwell Plate 
(Santa Clara, CA) with an injection volume of 8μL onto a Jupiter C4 capillary column 
(150 x 0.5mm) from Phenomenex (Torrance, CA).  The mobile phase for the HPLC 
experiment consisted of a gradient mixture of two solvents with a flow rate of 10μL per 
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second:  (A) 0.1% (v/v) formic acid in DI H2O, and (B) 0.1% (v/v) formic acid in ACN.  
The separation scheme involved a mixture of 95% of solvent (A), and 5% of solvent (B) 
held for 10 minutes and ramped to 100% of solvent (B) over 100 minutes, followed by 
holding 100% of solvent (B) for 20 minutes.  The column was then re-equilibrated at the 
initial mixture of 95% of solvent (A) and 5% of solvent (B) for 10 minutes prior to the 
next sample injection. 
 Mass spectrometry was performed on an Applied Biosystems Qstar Pulsar (I) 
(Foster City, CA), which contains a hybrid quadrupole-TOF detector (Figure 7).185  The 
electrospray source was operated in positive-ion mode at a voltage of 4.5 kV with 
scanning from 500 to 1,700 Da.  Instrument parameters were optimized with myoglobin. 
 
 
Figure 7.  Schematic of a Typical Quadrupole-TOF System 
 
2.2.6.5 CE Analysis of Apolipoproteins 
 Dried protein samples were reconstituted in 100uL of a buffer solution consisting 
of 12.5mM sodium borate, 3.5mM SDS (70%), and 20% (v/v) ACN prior to CE 
analysis.  A fused-silica capillary column with dimensions of 75μm i.d., 375μm o.d., 
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length to detector (Ld)of 50.6cm, and total length (Lc) of 60.7cm was used for the 
analysis.  On initial use, the capillary was rinsed with 1N NaOH for 10 minutes, 0.1N 
NaOH for 10 minutes, and DI H2O for 10 minutes.  Between all subsequent sample 
analyses, the column was rinsed with 1N NaOH for 2 minutes, followed by a rinse with 
buffer for 2 minutes.  The neutral marker consisted of a 0.5% (v/v) solution of DMSO in 
DI H2O.  CE analysis was performed on a Beckman P/ACE™ MDQ system (Fullerton, 
CA) that was equipped with a diode array detector.  Run parameters for a typical 
apolipoprotein separation were as follows: 
 
1. Rinse with buffer for 2 minutes 
2. Inject neutral marker at 0.5 psi for 5 seconds 
3. Inject sample at 0.5 psi for 5 seconds 
4. Apply voltage of 17.5kV for 30 minutes 
 
The resulting electropherograms were analyzed by 24 Karat software from Beckman 
(Fullerton, CA).  Quantification was performed at a wavelength of 214nm.   Calibration 
curves for apoA-I and apoC-I were created by serial dilution from 1.0mg/mL standards 
from Academy Biomedical (Houston, TX).  Identification of other apolipoprotein peaks 
was possible by comparison to previously published results.167, 180 
 
2.2.6.6 IEF Analysis of Apolipoproteins 
 Dried protein samples were reconstituted in 255uL of DeStreak™ rehydration 
solution and shaken for one hour at room temperature with a M71700 Slow Speed 
Rotomix® Variable Speed Rotator from Barnstead/Thermolyne (Dubuque, IA) prior to 
IPG gel application.  A 250uL aliquot of the sample mixture was then applied to a 13cm 
aluminum oxide strip holder and a 13cm, pH 4-7 Immobline™ DryStrip was placed gel-
side down into the holder.  Mineral oil was then layered on top of the strip and the cover 
strip was set atop the sample holder.  IEF IPG experiments were performed on an 
IPGPhor IEF Unit from Amersham Pharmacia Biotech (Piscataway, NJ) with a built-in 
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8,000V power supply and a Peltier solid state temperature control.  IEF parameters 
included a current of 50μA per strip at 20ºC and a run protocol consisting of a 12 hour 
rehydration step, followed by steps of 500V for 1 hour, 1,000V for 1 hour, and 8,000V 
for 4 hours. 
 Upon completion of the IEF experiment, a published method for staining with 
colloidal acid violet 17 was followed.169  Gels were removed from the strip holders and 
fixed for 30 minutes in a 20% (w/v) trichloroacetic acid solution, then de-fixed for 1 
minute in a 3% (v/v) solution of phosphoric acid.  The gels were then stained for 10 
minutes with a colloidal acid violet 17 solution consisting of 100mg of acid violet 17 
dissolved in 50mL of DI H2O and 50mL of 20% (v/v) phosphoric acid.  Gels were then 
de-stained during three 10 minute periods in 3% (v/v) phosphoric acid followed by three 
5 minute periods in DI H2O.  Images were acquired by placing the gels face down on a 
digital scanner and using Origin 7.0 software to visualize the negative image of the gel 
(akin to visualization of the bands in an UC tube).  The grayscale intensity of the IPG 
gels were plotted along the length of the strips, and pI values were determined by 
comparison to the pH gradient of the gel (Figure 8). 
 
 
Figure 8.  Gradient for Commercial IPG Strips, 13cm, pH 4-7 
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2.3 Clinical Studies 
2.3.1  Patient Selection 
 Two patient groups were selected:  control samples, and a CAD risk group.  The 
control group consisted of donors with normal to elevated HDL cholesterol, normal LDL 
cholesterol, and a clear angiogram.  The CAD risk group consisted of donors exhibiting 
normal to elevated HDL cholesterol and normal LDL cholesterol, but possessed 
documented CAD events. 
 
2.3.2   Smooth Muscle Cell Apoptosis 
 Selected samples of intact HDL-2 and HDL-3 were isolated using the freeze/slice 
method following preparative UC.  Samples were subjected to micro-concentration using 
filter units from Millipore (Billerica, MA) with a 10,000 molecular weight cutoff in 
order to remove the EDTA solute which would otherwise interfere with the apoptosis 
analysis.  Samples were then sterilized by means of a 0.2μm sterile filter unit from 
Millipore (Billerica, MA).  Following purification, samples were submitted to Johns 
Hopkins University to determine whether they induced apoptosis.  It was previously seen 
that samples of HDL from infants enriched with apoC-I, as well as pure human apoC-I 
markedly induced apoptosis in aortic smooth muscle cells (ASMC) via the N-SMase 
pathway.186  Studies were also performed to analyze apoptotic effects on human arterial 
endothelial cells (HAEC).  Submitted HDL fractions were analyzed for apoptotic effects 
on both cell types in order to gain understanding of the functionality of HDL subclasses 
between control patients, and those with recorded CAD events. 
 
2.3.3   Statistical Classification 
 In total, 15 control samples and 15 CAD samples were analyzed by lipoprotein 
density profiling followed by statistical analysis.  Lipoprotein density profiles were 
generated for each sample by using 0.2000M solutions of both NaBiY and Cs2CdY.  
Following lipoprotein density profiling, the area under the curve of various lipoprotein 
subclasses were obtained with the peak integration software native to Origin software.  
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In the NaBiY solute system 12 subclasses were identified:  b-TRL, d-TRL, LDL-1, 
LDL-2, LDL-3, LDL-4, LDL-5, HDL-2a, HDL-2b, HDL-3a, HDL-3b, and HDL-3c.  In 
the Cs2CdY solute system, the buoyant subclasses of LDL-1 and LDL-2 were not 
resolved from the TRL fractions, and only 10 subclasses were used in classification.  
The integrated intensities were then analyzed by LDA and SAVE using SPSS statistics 
software (Chicago, IL). 
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CHAPTER III 
RESULTS AND DISCUSSION* 
 
 The overall objective of this study was to develop a combination of information-
rich methods for the analysis of clinical samples in order to determine an individual’s 
risk of developing CAD.  To meet this objective, several developmental studies were 
conducted and methods were eventually combined into a clinically viable protocol once 
they were established.  The first steps toward this goal involved more thoroughly 
understanding how parameters in DGU can be altered in order to achieve an optimal 
separation of lipoprotein classes.  After a successful initial study with the cesium salt of 
bismuth EDTA (CsBiY), it was decided that research should focus on understanding 
how other heavy-metal complexes of EDTA can be utilized to manipulate the shape of a 
density gradient following a UC experiment. 
 Results of this experiment revealed novel properties of the di-cesium cadmium 
salt of EDTA, Cs2CdY, such as a low UV absorbance, high electrophoretic mobility, and 
high solubility.  These properties made Cs2CdY an ideal complex for applications that 
followed preparative UC.  Additional studies were then initiated to establish optimal 
conditions utilizing this EDTA complex as a preparatory step for electrophoresis, mass 
spectrometry, and isoelectric focusing experiments. 
    
 
 
 
____________ 
*Reprinted with permission from “Metal Ion Complexes of EDTA for Density Gradient 
Ultracentrifugation:  Influence of Metal Ions” by Johnson, J.D.; Bell, N.J.; Donahoe, 
E.L.; Macfarlane, R.D.; Anal. Chem., 2005, 77, 7054-7061, Copyright 2005 (ACS 
Publications) and from “UC/MALDI-MS Analysis of HDL:  Evidence for Density-
Dependent Post-Translational Modifications” by Johnson, J.D.; Henriquez, R.R.; Tichy, 
S.E.; Russell, D.H.; McNeal, C.J.; Macfarlane, R.D.; IJMS, 2007, 268, 227-233, 
Copyright 2007 (Elsevier) 
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As the research project evolved, strong evidence began to emerge that could 
potentially link cardiovascular risk with atherogenic HDL.  Conditions for isolating 
lipoprotein classes by DGU were established, and the project then focused on isolation 
of HDL subclasses for further study.  A protocol was developed to isolate these 
fractions, and then delipidate them for study of the apolipoproteins contained in the 
HDL-2 and HDL-3 subclasses by other methods.  A study utilizing serum samples from 
a library of patients containing samples from healthy volunteers, i.e. the controls, and 
those from patients with diagnosed cardiovascular events was then initiated in order to 
compare information from this combination of methods between the two cohorts.  
  The research described here presents an approach in combining various 
analytical techniques to not only more thoroughly analyze the complex distribution of 
apolipoproteins present in a sample of human serum, but to help increase sample 
throughput in a clinical setting as well. 
  
3.1 Analytical Methods 
3.1.1  Development of EDTA Complexes 
 The objective of this study was to develop a library of aqueous metal-ion 
complexes of EDTA that can be used to generate a family of density gradients in the UC 
for highlighting features of the serum lipoprotein particle density profile for clinical 
studies. This study investigated the properties of the metal ion-EDTA solute systems in 
more detail, focusing on the influences resulting from changing both the complexing ion 
and the counter-ion of the EDTA complex.  In particular, emphasis was placed on 
complexing metal ions ranging from 55 to 209 Da, and counter-ions containing sodium 
or cesium.  A synthesis scheme was developed to synthesize various EDTA complexes 
while eliminating undesirable by-products.  The properties examined included density, 
refractive index, solubility, absorptivity, interaction with the fluorophore NBD (C6-
ceramide), and ability to generate a self-forming density gradient when spun in a UC for 
lipoprotein density profiling. 
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3.1.1.1  Synthesis of EDTA Complexes 
 The various EDTA complexes were synthesized by combining the fully 
protonated H4EDTA, alkali carbonate, and the heavy metal oxide, hydroxide, carbonate, 
or oxycarbonate in DI H2O.  The rather insoluble H4EDTA and heavy metal compounds 
are stirred and heated to reflux for two hours, yielding a clear solution.  It was 
discovered that better control of the final solution could be attained by adding a half-
equivalent of the alkali carbonate during the reflux step, and titrating the final solution to 
a pH between 6.75 and 7.25 with the remaining alkali carbonate.  Once neutrality was 
achieved, the solution was added to a volumetric flask and reconstituted to the desired 
volume.    
 
3.1.1.2  Properties of EDTA Complexes 
 A stock solution of 0.4000M ± 0.0040M of each EDTA complex was used to 
create serial dilutions that would cover the dynamic range of concentrations expected in 
a UC experiment.  The density of each solution was determined gravimetrically by 
recording the weight of a 1,000μL aliquot from a 1,000μL micropipette.  A 20μL aliquot 
was used to determine the refractive index at room temperature as seen in the example 
data table and calibration plots for the solute Cs2CdY (Table 4) (Figure 9).  By using the 
same method values for these measurements were used to generate a calibration curve 
linking the density and refractive index for each solution (Table 5).   This relationship 
was given by the following equation, where ρ is the solution density, m is the slope of 
the curve, η is the refractive index of the solution, and yo is the y-intercept. (Eq. 21) In 
each case, this relationship was found to be linear over the density range of interest (1.00 
to 1.30 g/mL).  The slopes of the density/refractive index relationship correlated linearly 
with the molecular weight of the solutes. 
 
om yρ η= +           (21) 
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Table 4.  Calibration of Density vs. Refractive Index for Cs2CdY 
Concentration (M) Density (g/mL) η 
0.3994 1.1899 1.3600 
0.3728 1.1787 1.3582 
0.3462 1.1674 1.3566 
0.3195 1.1491 1.3543 
0.2929 1.1447 1.3530 
0.2663 1.1237 1.3509 
0.2396 1.1187 1.3490 
0.2130 1.1050 1.3471 
0.1864 1.0949 1.3452 
0.1598 1.0842 1.3436 
0.1331 1.0708 1.3419 
0.1065 1.0599 1.3378 
0.0799 1.0473 1.3400 
0.0533 1.0296 1.3360 
0.0266 1.0229 1.3340 
0.0000 0.9955 1.3320 
 
 
 
Figure 9.  The Linear Relationship of Concentration, Density and, Refractive Index for 
Cs2CdY 
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Table 5.  Equation Values for Density vs. Refractive Index Formula 
Salt MW (g/mole) Slope (m) Y-Intercept (y0) R2
CsBiEDTA 630.0938 5.4548 -6.2502 0.9954 
NaBiEDTA 520.1782 4.7647 -5.3525 0.9896 
Cs2PbEDTA 761.2093 6.7665 -8.0089 0.9956 
Na2PbEDTA 541.3780 5.016 -5.6811 0.993 
Cs2CdEDTA 666.4193 6.612 -7.8024 0.9961 
Na2CdEDTA 446.5880 4.4776 -4.9596 0.9904 
Na2CuEDTA 397.7280 4.0663 -4.4191 0.9901 
NaFeEDTA 367.0452 3.3795 -3.5019 0.9885 
 
    Solutions of each of the EDTA complexes at a concentration of 0.2000M were 
then spun in a UC for 6 hours at 120,000 RPM and 5ºC in order to determine their 
gradient-forming capabilities.  The density profiles generated during UC were measured 
by sampling the resulting solution at specific depths and measuring the refractive 
indices.  The depths were determined by capturing an image of the pipette inside the UC 
tube with the camera used for lipoprotein density profiling.  These values were then used 
to calculate the density of the solution at specific tube coordinates in order to determine 
the shape of the gradient.  The density profile data was fitted to an exponential function 
where ρ is the solution density in g/mL, x is the tube coordinate in mm, A and B are 
constants generated by Origin’s peak fitting module, and yo is the y-intercept (Eq. 22) 
(Table 6). 
 
( )x B
oAeρ = + y          (22) 
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Table 6.  Density Profile Equations for Each Solute System 
Salt A B Y-Intercept (y0) R2
CsBiEDTA 0.0004 4.4632 1.0284 0.9864 
NaBiEDTA 0.0004 4.8752 1.0177 0.9918 
Cs2PbEDTA 0.0158 10.2158 0.9846 0.9895 
Na2PbEDTA 0.0122 12.0084 1.0061 0.9875 
Cs2CdEDTA 0.01937 12.2364 0.9860 0.9827 
Na2CdEDTA 0.0172 17.5396 1.0051 0.9918 
Na2CuEDTA 0.0106 16.3193 1.0114 0.9919 
NaFeEDTA 0.0038 11.0600 1.0114 0.9935 
 
It was observed that solutes with a higher molecular weight yielded a steeper 
density gradient.  The previous discussion of sedimentation theory in the materials and 
methods sections dictated that the molecular weight of the chosen solute system affected 
the slope of the density gradient during a UC experiment (Eq. 10).  A linear relationship 
between molecular weight and steepness of the density profile was expressed by plotting 
the natural logarithm of the concentration ratios (c2/c1) of the solute versus the square of 
the difference in their tube coordinates (r22-r12).  
 
2 1
2 2 2
2 1
ln( )(2 )
(1 ) ( )
c c RTM
r rυρ ω= − −         (10) 
 
By substituting the density of the solution for the the (c2/c1) term and replacing the 
solution coordinate term (r22-r12) with the tube coordinate of a UC tube squared (x2), then 
solving the equation for the natural log of the density, the equation becomes: (Eq. 22)  
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(2 )
M x
RT
υρ ωρ −=         (22) 
 
By plotting the natural log of the density against the square of the tube coordinate, an 
equation of the form (y = mx + b) can be generated, thereby allowing comparisons to be 
made between different EDTA complexes (Figure 10).4 
 
 
Figure 10.  Plot of ln(Density) vs. Coordinate2 for 0.2000M Solutions of NaBiY -■-, 
Na2PbY -●-, Na2CdY -▲-, and NaFeY -♦-. 
      
The partial specific volume of the solute,υ , its density, ρ, the angular velocity of the UC 
rotor, ω, and the temperature, T, influenced the slope of this linear function.  For sodium 
salts of the various EDTA complexes, it was observed that complexing metal ions with 
higher molecular weights yielded steeper slopes, as was the case with NaBiY and 
Na2PbY (Table 7).   
 
 
 
 
 55
Table 7.  Equation Values for ln(Density) vs. (Coord)2 Formula 
Salt MW Slope Intercept R2
NaBiY 520.2 1.300 x 10-4 1.012 x 10-2 0.9930 
Na2PbY 541.4 1.100 x 10-4 3.048 x 10-2 0.9963 
Na2CdY 446.6 7.000 x 10-5 3.059 x 10-2 0.9889 
NaFeY 367.0 5.000 x 10-5 2.005 x 10-2 0.9981 
 
It was also observed that the complexes containing divalent metals, Na2PbY and 
Na2CdY also shared a higher intercept than complexes with trivalent metals, NaFeY and 
NaBiY.  The combination of slope and intercept showed that both the complexing metal 
ion and counter ion are important to determining the effect of molecular weight on the 
shape of the density curve.  Furthermore, by plotting the slope obtained from these linear 
functions against the molecular weight of the solute being used, it was seen that there 
was a good correlation between several different solute systems with an R2 of 0.9556 
(Figure 11). 
 
 
Figure 11.  Slope of Density Equation vs. MW of Solute System Used 
 
 The use of the UC served a dual role of providing a useful lipoprotein density 
profile and a means of pre-separating the lipoprotein subclasses prior to secondary 
analysis.  Since UV absorbance was a critical part of CE experiments, it was necessary 
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to gain understanding about how the absorbance properties of different solute systems 
could potentially interfere with this analysis.  It was previously shown by our laboratory 
that bismuth complexes of EDTA displayed a very high UV absorbance. This resulted in 
such a high level of interference that CE experiments were not possible without labor 
intensive removal of the salt.  With the exception of the copper and iron complexes, the 
various solutions were transparent in the visible region but absorbed in the ultraviolet 
region. Interestingly, the maximum absorbance wavelength of each solution was 
strongly dependent on the metal ion that is chelated to the EDTA ligand (Figure 12). 
 The bismuth complexes displayed very high absorbance maximums at 241nm 
and 264nm, while the lead complexes displayed equally high absorbances at 210nm and 
241nm.  The complexes containing cadmium had a much lower absorbance at a 
wavelength of 206nm.  The complexes containing iron and copper displayed a very 
broad absorbance that covered most of the ultraviolet region and also a strong visible 
absorbance.  The absorbance of the copper complex was very intense between 400-
500nm, which overlapped with the absorbance maximum of the NBD (C6-ceramide) 
fluorophore at 460nm.  The absorbance of the iron complex was very intense between 
500-700nm, which overlapped with the emission spectra of NBD (C6-ceramide).  The 
overlap of the absorbance and emission spectra of the fluorophore with these two EDTA 
complexes contributed to interference with imaging, as is discussed in the lipoprotein 
density profiling section. 
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Figure 12.  UV Absorbance Spectra of the Solute Systems:  (A) CsBiY -▲-, NaBiY -●-, 
(B) Cs2PbY -▲-, Na2PbY -●-, (C) Cs2CdY-▲- , Na2CdY -●-, (D) Na2CuY -▲-, and 
NaFeY -●- at a Concentration of 0.4000M. 
 
 Looking at the absorbance spectra for each complex, it was seen that altering the 
counter-ion of the complexes of Bi+3, Pb+2, and Cd+2 between Na+ and Cs+ had no 
discernible effect on the UV absorbance.  The absorbance maxims are the same for both 
counter-ions, and even the absorbance intensity remained unchanged when comparing 
the two.  A set of dilutions in the linear range for each stock solution was made to 
determine the molar absorptivity of each EDTA complex by Beer’s Law (Table 8). 
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Table 8.  Molar Absorptivity at the Maximum Absorbance Wavelength 
Salt Wavelength (nm) ε (L cm-1mole-1) 
CsBiEDTA 264 7,889 
NaBiEDTA 264 7,855 
Cs2PbEDTA 241 7,527 
Na2PbEDTA 241 7,517 
Cs2CdEDTA 206 780 
Na2CdEDTA 204 717 
Na2CuEDTA 250 2,219 
NaFeEDTA 256 7,029 
 
It was shown that complexes containing the same complexing ion but different 
counter-ions had very similar absorption properties.  Complexes containing cadmium 
had an approximately ten-fold reduction in molar absorptivity from the others.  The 
absorptivity of complexes containing the Bi3+, Pb2+, and Cd2+ ions occurred as a result of 
ligand to metal charge transfer (LMCT) and were examined elsewhere.187-190 This effect 
was seen because the Bi3+ and Pb2+ ions are capable of undergoing charge transfer 
between the ligand and metal, whereas this process is presumably less favorable for the 
Cd2+ ion due to its filled d-shell and empty p-shell.  Since EDTA is a hexadentate ligand, 
considerable charge transfer was possible due to the number of coordination sites from 
which the ligand can chelate to the metal ion.  The strong interaction between the 
complexing metal ion and the EDTA ligand was also reflected by their high formation 
constants.191 
 
3.1.1.3  Counter-ion Effect 
It was observed by refractometry that solutions of complexes containing the Cs+ 
counter-ion yielded a steeper density profile than those containing the Na+ counter-ion in 
each case due to the inherently higher molecular weight of these complexes.  It was also 
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noticed that when a serum sample is spun in a solute containing Cs+, the corresponding 
density of the lipoprotein subclasses were higher than those spun in a solute containing 
the Na+ ion (Table 9). Lipoproteins are macromolecular anions at a pH of 7, so the Na+ 
and Cs+ ions will form an ionic atmosphere around them and increase their density 
relative to their natural state. Since the Cs+ ion is heaver than the Na+ ion, the density of 
the lipoprotein was greatly altered by substituting the counter-ion of the EDTA complex. 
These findings suggested that the ionic atmosphere configuration is retained under the 
influence of the forces operating during UC as the lipoproteins migrated to their 
isopycnic positions.  When comparing densities obtained from solutes containing either 
Na+ or Cs+, the densities differed by as much as 0.0192 g/mL for LDL and 0.0294 g/mL 
for HDL.  This result was verified by the relatively low RSD% of 0.0083, indicating that 
the difference in densities was not due to a lack of precision in the measurement of 
refractive index, which was precise up to four decimal places. 
 
Table 9.  Effect of Counter-ion on Density of Lipoproteins 
Solute LDL Density (g/mL) HDL Density (g/mL) 
CsBiEDTA 1.0588 1.1473 
NaBiEDTA 1.0396 1.1179 
Cs2PbEDTA 1.0571 1.1296 
Na2PbEDTA 1.0480 1.1204 
Cs2CdEDTA 1.0574 1.1378 
Na2CdEDTA 1.0491 1.1002 
 
3.1.1.4  Lipoprotein Density Profiling 
During developmental work, various UC rotor speeds and times were studied to 
determine the optimal conditions for separating lipoprotein subclasses. The maximum 
rotor speed of 120,000 rpm was chosen to optimize the equilibration process between 
sedimentation and diffusion of the particles contained in the UC tube and yielded a 
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sufficient separation of the lipoprotein molecules.3  Solutions containing complexes of 
CsBiY, NaBiY, Cs2PbY, Na2PbY, Cs2CdY, and Na2CdY were each observed to give 
unique separations of the different lipoprotein subclasses (Figure 13).   In the six 
lipoprotein density profiles below, a distinct difference in separation was achieved by 
using equi-molar concentrations of the various EDTA solutes.     
The two primary methods of modifying the lipoprotein density profiles discussed 
here involve altering the concentration of the gradient-generating solute or by changing 
the solute system altogether. In the case of the latter, it becomes possible to tailor the 
lipoprotein profiles to enhance specific areas, such as the region between VLDL and 
LDL or the region between LDL and HDL. An example of this application would be in 
the study of Lp(a) that is located between the LDL and HDL regions of the lipoprotein 
profile.  Solutions of Na2PbY and Na2CdY at a concentration of 0.2000M, panels D and 
F, respectively, would give the best separation for this region of interest.   
In EDTA complexes containing Bi+3, a near-baseline separation was achieved 
among all five regions as seen in panels A and B although the separation between VLDL 
and LDL was greater when using CsBiY, while the separation between LDL and HDL 
was greater when using NaBiY.  Looking at the separation achieved by CsBiY in panel 
A and NaBiY in panel B, the slope of the density curve was very steep, which explains 
the good separation of different lipoprotein classes.  In addition, since the density profile 
was not as steep for the NaBiY solution, the resulting LDL and HDL subclasses tended 
to be expanded more than when using CsBiY as the density gradient generating medium. 
This verified that simply changing the counter-ion from cesium to sodium can have a 
large impact on the resulting density gradient. 
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Figure 13. Lipoprotein Density Profiles Obtained with 60μL of Serum and Spun in 
0.2000 M Solutions of (A), CsBiY, (B) NaBiY, (C) Cs2PbY, (D) Na2PbY, (E) Cs2CdY 
and (F) Na2CdY for 6 Hours at 120,000 RPM and 5°C. 
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When Pb2+ was used as the complexing metal ion, as opposed to Bi3+, two 
counterions of Cs+ or Na+ will be associated with the EDTA complex, resulting in 
compounds of Cs2PbY and Na2PbY that have a higher molecular weight than the 
corresponding bismuth complexes. In the cases seen in panels C and D, the shape of the 
density gradient resulted in an expansion of the HDL region relative to that seen in 
panels A and B, and the LDL region was forced to a lower position on the tube 
coordinate scale (i.e., closer to the meniscus). Because the gradient is more linear and 
shallow in the Pb+2 complexes than the Bi+3 complexes, the separation between LDL and 
HDL was not as good. 
As in the case of the Pb+2 systems, when Cd+2 was used as the complexing metal 
ion, two counterions will associate with the EDTA complex.  The result was that the 
Cd+2 complexes had a molecular weight between the Bi+3 and Pb+2 complexes.  In the 
Cs2CdY solute system seen in panel E, the slope of the density gradient was less steep 
than the Cs2PbY system seen in panel C, causing the HDL and protein regions of the 
lipoprotein profile to shift to a higher position on the tube coordinate scale for the Pb+2 
system.  There was essentially no difference in the LDL region of the lipoprotein profiles 
between these two solute systems.  The density gradient formed by Na2CdY in panel F, 
however, was relatively linear, resulting in two noticeable alterations to the lipoprotein 
profile.  Since the density of this complex did not exceed 1.10 g/mL, the HDL contained 
in the sample was not separated from the higher density protein region.  Additionally, 
the LDL region of the profile was elongated to such an extent that three discernible 
subclasses were seen for this particular sample. 
The low molecular weight complexes of Na2CuY and NaFeY yielded density 
gradients that were shallower than the solution of Na2CdY, thereby making them 
impractical for separating the different lipoprotein subclasses.  In addition, the NBD (C6-
ceramide) intensities for the lipoprotein subclasses are considerably smaller than for the 
other solute systems mainly due to the overlap of the absorbance and emission spectra 
between the fluorophore and the copper and iron complexes (Figure 14).  The only 
regions of the lipoprotein profiles that were visible were the chylomicron/meniscus and 
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VLDL regions, where the concentrations of these EDTA complexes were significantly 
lower in the region at a low tube coordinate.  Fluorescence quenching also occured as a 
result of binding of the NBD (C6-ceramide) fluorophore to Fe3+ ions.192  Binding of Fe3+ 
to fluorophore competes with binding of Fe+3 to the EDTA ligand and can only be 
reversed at low pH with an excess of EDTA present.193  The combination of 
absorbance/emission interference between Fe+3 and Cu+2 ions and NBD (C6-ceramide) 
along with fluorescence quenching makes these solute systems impractical for 
lipoprotein density profiling.  Since Cu2+ is also a transition metal with an empty d-
orbital, quenching occured here as well, although to a lesser extent, since the copper ion 
is more tightly bound to the EDTA ligand.194-196  This result was particularly interesting 
because it indicated that these paramagnetic ions must be in close proximity to the NBD 
(C6-ceramide) fluorophores that were imbedded in the hydrophobic domains of the 
lipoproteins. 
The EDTA solute systems allowed for isopycnic separation of lipoproteins 
beginning with a homogenous solution.  The use of EDTA solutes also offered the 
advantage of having a flexible molecular weight due to the ability to substitute both the 
counter-ion and complexing ion. By simply altering these ions, varying degrees of 
separation were achieved in order to tailor a separation for a specific class of 
lipoproteins if so desired. 
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Figure 14.  Fluorescence Quenching of NBD (C6-ceramide) in the Lipoprotein Density 
Profiles Obtained from 60μL of Serum Spun in 0.2000M Solutions of (A) Na2CuY and 
(B) NaFeY, for 6 Hours at 120,000 RPM and 5ºC. 
 
   The true benefit of the ability to tailor the DGU separation with the various 
EDTA solutes was shown when the method was used in a preparative mode for further 
analyses.  With full control over the complexing metal ion and counter-ion, as well as 
the concentration of the solution, it became possible to isolate specific regions of the 
lipoprotein profile for subsequent experimentation.  Since the Cd+2 complexes are 
doubly-charged (i.e.  CdY-2) and had a relatively low absorptivity as opposed to the 
much higher absorptivity of the singly charged Bi+3 complexes (i.e. BiY-1), it was 
determined that they are a better choice of solute for preparative UC.  Their ability to 
separate lipoprotein subclasses effectively coupled with their favorable absorbance and 
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electrophoretic properties made them ideal solutes for preparation of CE and MS 
experiments. 
 
3.1.1.5 Preparative Ultracentrifugation 
The goal of preparative UC experiments was to cleanly isolate the region of 
interest in a lipoprotein profile in order to extract it for secondary analysis.  Since the 
aim of this research was to study atherogenic particles of HDL, this approach involved 
two further developmental steps once Cs2CdY was determined to be the density gradient 
solute of choice.  First, the required concentration of Cs2CdY to isolate the HDL region 
was determined by UC of the solute at various concentrations ranging from 0.2000M to 
0.4000M.  It was found that a solute concentration of 0.3000M gave the optimal 
isolation of the HDL region.  Secondly, it was desirable to remove all apo-B containing 
lipoproteins from solution prior to UC in order to minimize interference from LDL and 
Lp(a).  The standard method for HDL quantification involved precipitation of Apo-B 
containing lipoproteins by addition of a DS reagent to whole serum prior to UC.182  This 
reagent was generated as described in the materials and methods section.  This mixture 
was then added to whole serum in a 1:10 ratio (v/v) and allowed to incubate for 10 
minutes at room temperature, followed by centrifugation at 12,000 rpm on a tabletop 
centrifuge.  The supernatant was recovered and was prepared for lipoprotein density 
profiling as if it were a normal whole serum sample.  A comparison between the 
lipoprotein density profiles of a normo-lipidemic patient spun in 0.2000M NaBiY with 
and without the DS precipitation step showed that this procedure very cleanly removed 
all apo-B containing lipoproteins from the serum profile (Figure 15).  By combining the 
DS precipitation steps with a UC spin using 0.3000M Cs2CdY, it became possible to 
freeze the sample and excise out fractions of the buoyant HDL-2 fraction and the dense 
HDL-3 fraction for clinical studies (Figures 16-17). 
 
 66
 
Figure 15.  Comparison of Lipoprotein Density Profiles for Whole Serum to 
Supernatant of DS Precipitation in a 0.2000M Solution of NaBiY, Spun for 6 Hours at 
120,000 RPM and 5ºC. 
 
In the density profiles of the patient samples it was observed that there was 
baseline separation of the entire HDL zone from other lipoproteins.  In total, there were 
12 samples analyzed in this study, 6 controls, and 6 with a pre-existing condition of 
CAD.  For the duration of this dissertation, the focus will remain with one control, 
sample #47, and one CAD patient, sample #10, with data for the other 10 samples 
contained in the appendix.  Of interest was that in samples designated as controls, there 
appeared to be a higher distribution of HDL towards the denser HDL-3 subclass, while 
in CAD samples, the shift favored the buoyant HDL-2 subclass.  In none of the samples 
analyzed was there baseline separation between the two HDL subclasses.   
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Figure 16.  Lipoprotein Density Profile of Sample #47 in a 0.3000M Solution of 
Cs2CdY, Spun for 6 Hours at 120,000 RPM and 5ºC after DS Precipitation. 
 
 
Figure 17.  Lipoprotein Density Profile of Sample #10 in a 0.2000M Solution of 
Cs2CdY, Spun for 6 Hours at 120,000 RPM and 5ºC after DS Precipitation. 
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3.1.2  Delipidation and Purification of Apolipoproteins 
 For apolipoprotein analysis of HDL, the excised fraction must be subjected to a 
delipidation step prior to secondary analysis.  This involved the use of a solid phase 
extraction (SPE) cartridge which served to both de-salt, and to remove the lipid content 
of the sample, operating much like a reverse-phase liquid chromatography experiment.  
SPE experiments were performed as described in the materials and methods section, and 
served to elute the polar components of a sample fraction, while retaining the most non-
polar lipid components.  MALDI-MS was utilized to determine the elution profile from 
the SPE cartridge.  Four aliquots of 50μL eluents were obtained, and each was prepared 
for MALDI-MS analysis by use of a C4 ZipTip, which behaved like a very small scale 
reverse-phase column.  A 5μL aliquot of each sample was concentrated in the ZipTip, 
and then eluted with a solution consisting of 60% ACN, 0.1% TFA, and 40% DI H2O by 
volume.  The effluent was then mixed with a 5μL volume of a solution containing 
15mg/mL of ferulic acid in 60% ACN, 40% DI H2O, and 0.1% TFA by volume and then 
evaporated to dryness.  It was found that any HSA remaining after the wash steps 
primarily eluted from the SPE cartridge in the first 50μL aliquot, while the remaining 
apolipoproteins of HDL eluted in the first through fourth aliquots (Figure 18).  In this 
particular case, however, no HSA was detected in the MALDI mass spectrum.  Typically 
the wash step was enough to fully remove all of the HSA, but it was observed in the first 
aliquot if it was not completely removed.  It was seen in panels A, B, and C that the 
expected apolipoproteins were eluted from the SPE column.  It was also observed that 
the majority of the apolipoproteins eluted during the first and second 50μL aliquots, and 
that nothing above baseline could be seen in the fourth 50μL aliquot in panel D.  It is 
also important to note that apo A-II was not fully eluted until after the third aliquot, 
while apo A-I appeared to be fully eluted by the second aliquot.  This result gave 
evidence that even though apo A-I is a larger apolipoprotein, apo A-II as a dimer is more 
hydrophobic.  As a result, the first four aliquots from samples delipidated by SPE were 
pooled together for all HDL fractions to be analyzed to ensure maximum recovery. 
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Figure 18.  Elution Profile for SPE of HDL Apolipoproteins for the 1st (A), 2nd (B), 3rd 
(C), and 4th (D) 50μL Effluents 
 
3.1.3  Desalting and Purification of Intact Lipoproteins 
For analysis of intact lipoproteins,the sample must be de-salted without removing 
the lipid content of the apolipoprotein.  Because of this stipulation, de-salting must be 
performed by way of micro-concentration of the excised fraction.  Micro-concentration 
of excised samples allowed for replacement of the EDTA solute with a suitable solution 
for apoptosis studies, such as DI H2O.  Samples were typically micro-concentrated from 
a volume of 500μL down to 50μL, and then reconstituted back to 500μL for each cycle.  
It was seen that five reconstitution cycles gave adequate removal of the undesired EDTA 
solutes.  Following micro-concentration, samples were then sterilized by means of a 
0.22μm syringe filter unit.  For studies involving apoptosis, it was important to both 
desalt and sterilize the HDL samples to limit the amount of background apoptosis that 
would interfere with the analysis. 
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3.1.4   MALDI-MS Analysis of HDL Fractions 
The objective of this study was to determine whether the nature of the post-
translational modifications of the major apolipoproteins of HDL was different for 
density-distinct subclasses.  The serum of two subjects, a control with a normo-lipidemic 
profile, and a subject with diagnosed cardiovascular disease, were studied.  Aliquots of 
three HDL subclasses were analyzed by MALDI and considerable differences were seen 
when comparing density-distinct subclasses and also when comparing the two subjects.  
A detailed analysis of the post-translational modification pattern of apoA-1 showed 
evidence of considerable protease activity, particularly in the more dense fractions. It 
was hypothesized that part of the heterogeneity of the population of HDL particles is due 
to density-dependent protease activity. 
This study was aimed at understanding density-distinct differences between HDL 
subfractions.  It was discovered that the 0.3000M Cs2CdY solution could be utilized to 
isolate three regions in the HDL profile.  There regions were labeled “buoyant”, 
“middle”, and “dense” HDL during this study.  After UC, samples were frozen and 
excised as previously described, then desalted and purified for MALDI-MS (Figure 19).   
 
 
Figure 19.  Preparative UC Profiles of Control and CAD Samples for Buoyant (A), 
Middle (B), and Dense (C) HDL Fractions 
 
A 5μL aliquot of each HDL fraction was concentrated by using a C4 ZipTip and 
eluted with a solution consisting of 60% ACN, 0.1% TFA, and 40% water (v/v) The 
 71
effluent was then mixed with a 5μL volume of a solution consisting of ferulic acid (15 
mg/mL) in 40% H2O, 60% ACN, 0.1% TFA (v/v) and evaporated to dryness on a 
MALDI plate. 
 
3.1.4.1 Post-Translational Modifications in MALDI-MS 
Three suspected differences that could be seen in MALDI-MS include: oxidative 
processes that could modify the HDL apolipoproteins, presence or absence of 
inflammatory response markers, and the possibility of post-translational modifications of 
the major apolipoproteins.  Oxidation and post-translational modifications would be 
revealed in MALDI-MS by shifts in m/z distributions for the various apolipoproteins.  
The presence or absence of specific proteins, such as SAA, could indicate an 
inflammatory response.  It was uncertain as to whether these conditions would appear 
across the entire density range of HDL, so MALDI spectra were recorded for the three 
HDL subfractions for a normo-lipidemic patient and a patient with diagnosed 
cardiovascular events (Figure 20).  This experiment reports the results of a feasibility 
study in determining what differences, if any, can be observed by analyzing both 
density-distinct, and patient specific sample fractions.  At first glance, the spectra were 
qualitatively similar to what was observed in previous studies, with the dominant peaks 
coming from: apoA-I,II, and apoC-I,II,III.141 The m/z peaks due to apo C-I dominated 
the spectra despite the low abundance of this apolipoprotein compared to A-I.  This 
occurred due to a high concentration of lysine residues, which makes apo C-I more basic 
than the other apolipoproteins, and therefore gives it a higher proton affinity.     
What was remarkable about these spectra was that the pattern of post-
translational modifications showed significant differences for all three density regions of 
both a control sample and a CAD sample.  The accuracy of the mass measurements was 
not sufficient to identify every observed peak, but the majority of post-translational 
modifications could be accounted for (Table 10). 
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Figure 20.  MALDI Spectra of Control and CAD Samples for Buoyant (A), Middle (B), 
and Dense (C) HDL Fractions 
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Table 10.  Identification of Apolipoproteins in MALDI Spectra 
Identification Code Avg. Mass 
Apo C-I minus N-Thr-Pro C-I' 6,440.25 
Apo C-I  C-I' 6,639.30 
C-I plus 206 Da Adduct C-Iadd 6,845.72 
Apo C-II C-II 8,217.89 
Apo A-II minus C-Gln-Gln, z = 2 A-II'2+ 8,634.09 
Apo A-II Monomer minus C-Gln A-II'm 8,692.80 
Apo C-III0 C-III0 8,778.00 
Apo A-II Monomer A-IIm 8,819.47 
Pro Apo C-II pro C-II 8,924.90 
Galβ, 3GalNAc-O-C-III0 C-III0,Glyc 9,140.78 
Apo C-III1 minus C-Ala-Ala C-III1'' 9,301.33 
Apo C-III1 minus C-Ala C-III1' 9,363.79 
Apo C-III1 C-III1 9,429.98 
Apo C-III2 minus C-Ala-Ala C-III2'' 9,574.07 
Apo C-III2 minus C-Ala C-III2' 9,645.03 
Apo C-III2  C-III2 9,721.06 
SAA1 minus N-Arg SAA1' 11,536.64 
SAA1 SAA1 11,695.05 
SAA1 plus 189 Da Adduct SAA1,add 11,884.05 
SAA4 minus C-Lys-Lys-Tyr SAA4''' 12,464.63 
SAA4 minus C-Lys-Tyr SAA4'' 12,582.71 
SAA4 minus N-Glu-Ser SAA4n'' 12,674.19 
SAA4  SAA4 12,873.51 
Prealbumin Prealb 13,781.97 
Apo A-I minus C-Thr-Gln, z = 2 A-I''2+ 13,934.21 
Apo A-I minus C-Gln, z = 2 A-I'2+ 13,983.24 
Apo A-I, z = 2 A-I2+ 14,049.10 
Apo A-I plus 294 Da Adduct, z = 2 A-I2+add 14,343.10 
Apo A-II Dimer minus C-Thr-Gln and C-Gln A-IIt'' 17,042.71 
Apo A-II Dimer minus C-Gln-Thr-Ala A-II''' 17,085.79 
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Table 10.  (Continued) 
Identification Code Avg. Mass 
Apo A-II Dimer minus 2x C-Gln A-II'' 17,146.45 
Apo A-II Dimer minus C-Gln A-II' 17,267.74 
Apo A-II Dimer A-II 17,396.94 
Apo A-II Dimer plus 322 Da Adduct A-IIadd 17,718.94 
Apo A-I minus C-Gln A-I' 27,974.84 
Apo A-I A-I 28,111.50 
Apo A-I plus 554 Da Adduct A-Iadd 28,665.50 
 
Examining these spectra in greater detail revealed some significant differences. 
There appeared to be a marked change in the shape and intensity of the apo A-I peak as a 
function of density for both the control sample and the CAD sample.  This phenomenon 
was seen in greater detail when looking at expanded views of the doubly-charged ions of 
Apo A-I, as opposed to the singly-charged ions.  This observation was due to the higher 
resolution that was obtained in the lower m/z range where the doubly-charged ion was 
located (Figures 21-26).  We can only postulate that different proteases are resident on 
the HDL particles dependent on the density of the particle. There appeared to be more 
protease activity in the dense HDL component for the CAD subject. It was clear from 
these results that the nature of post-translational modifications was linked somehow to 
the density of the HDL particle. 
 Apo C-I and its truncated form Apo C-I’ were consistently observed for all six 
sample fractions and alterations in structure were not as prevalent as that which was seen 
for apo A-I.  Apo C-I’ differed in mass from Apo C-I by approximately 200 mass units 
as the result of truncation of two amino acid residues, threonine and proline, from the N-
terminus.143  Interestingly, the ratio of apo C-I’ to apo C-I appeared to be enhanced in all 
3 fractions of the CAD sample, with the greatest amount of enhancement seen in the 
buoyant fraction.   This result suggests that there may be a link between the relative 
amounts of the two isoforms of apo C-I that could assist in assessing an individual’s 
cardiovascular risk. 
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 Significant differences were also seen in the serum amyloid A (SAA) region of 
the MALDI spectrum for the two patients.  The isoform designated as SAA1 is indicative 
of an acute-phase response to inflammation while the isoform SAA4 is typically seen in 
normal serum.197, 198  A peculiar result was that both the control sample and the CAD 
sample contained each of these isoforms, but SAA1 was observed in every density 
fraction for the control patient and only in the dense fraction for the CAD patient. 
 There were two regions of the MALDI spectra that contained results that were 
largely the same throughout the various density ranges for both patients.  The apo A-II 
dimer was observed to contain the same distribution of isoforms regardless of which 
density region or patient from which it was obtained.  The intensity of the peaks in this 
portion of the spectra also tended to scale with the intensity of the rest of the mass 
spectra.  At the high molecular weight end of the mass spectra, the singly-charged apo 
A-I did not display well-resolved peaks as was seen in lower molecular weight regions 
of the spectra, and consisted primarily of the main apo A-I peak, a truncated apo A-I’, 
and an apo A-I’ containing a suspected adduct that added approximately 554 Da to its 
native mass.  As previously mentioned, the resolution of the doubly-charged ions of apo 
A-I were much improved and allowed for a more thorough analysis. 
 The busiest region of the mass spectra resided with the other apo C 
apolipoproteins and appeared as a “fingerprint” that was seemingly density dependent.  
In buoyant sample fractions, the apolipoproteins, and their modifications, C-III0, pro C-
II, and C-III1 appeared to be the most intense.  For dense sample fractions, the 
apolipoproteins, and their modifications, A-II, and C-III2 appeared to be the most 
intense.  The HDL fraction in between these two densities displayed an intermediate 
intensity for each apolipoprotein.  Substantial differences between the control and CAD 
samples were not observed in this region. 
 By coupling mass analysis by MALDI-MS with the sample preparation 
developed with DGU, these results demonstrated feasibility in a new approach to better 
understanding the apolipoprotein distribution for patient samples as a function of 
density. 
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Figure 21.  MALDI-MS Spectrum for Buoyant Fraction of Control Sample 
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Figure 22.  MALDI-MS Spectrum for Middle Fraction of Control Sample 
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Figure 23.  MALDI-MS Spectrum for Dense Fraction of Control Sample 
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Figure 24.  MALDI-MS Spectrum for Buoyant Fraction of CAD Sample 
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Figure 25.  MALDI-MS Spectrum for Middle Fraction of CAD Sample 
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Figure 26.  MALDI-MS Spectrum for Dense Fraction of CAD Sample 
 
3.1.5   LC-MS Analysis of HDL Fractions 
 LC-MS was utilized as a means of looking at inherent differences in 
apolipoprotein structure and abundance for density-distinct fractions of HDL in both 
control and CAD samples.  To achieve these goals, an external standard calibration 
curve was generated for the apolipoproteins apo A-I and apo C-I in order to determine 
whether the concentration of the suspected atherogenic apo C-I played a role in 
cardiovascular risk.  The mass distributions of the major apolipoproteins of HDL were 
also studied from the electrospray ionization (ESI) mass spectra. 
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3.1.5.1  Identification and Quantification of HDL Apolipoproteins by LC Trace 
 Serial dilutions were performed on stock 1.000mg/mL standard solutions of apo 
A-1 and apo C-1 in order to generate a concentration range that would include the 
dynamic range of each apolipoprotein expected in a serum sample.  The average 
concentration of apo C-I is a factor of twenty times less than that of apo A-I in normo-
lipidemic serum, which was reflected in the establishment of these calibration curves.  
The instrumental parameters for the LC-MS experiment were as described in the 
materials and methods section.  Integration of the LC trace was performed with Origin 
software in order to link the concentration of the apolipoprotein with the response of the 
instrument (total ion current).  The LC traces of both apolipoprotein standards indicated 
that there was a considerably large polar component that eluted earlier than the 
apolipoproteins themselves (Figures 27-33).  Electrospray data revealed that these large 
peaks were low-molecular weight impurities in the standards.  It was seen that peaks 
centered about a retention time of 65min were indicative of apo A-I, and peaks that were 
centered about 57min were indicative of apo C-I.  The lowest concentration of apo A-I 
that was visible in the LC-trace was 62.5μg/mL, while the lowest concentration of apo 
C-I was 25.0μg/mL.  The expected dynamic range in a serum sample for apo A-I and 
apo C-I was 100-150mg/dL (1,000-1500μg/mL) and 3-6mg/dL (30-60μg/mL) 
respectively.  Since HDL was split into two fractions, expected concentrations in a given 
sample should be roughly half of these values.   
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Figure 27.  LC Trace of Apo A-I Standard at a Concentration of 50.0mg/dL 
 
 
Figure 28.  LC Trace of Apo A-I Standard at a Concentration of 25.0mg/dL 
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Figure 29.  LC Trace of Apo A-I Standard at a Concentration of 12.5mg/dL 
 
 
Figure 30.  LC Trace of Apo A-I Standard at a Concentration of 6.25mg/dL 
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Figure 31.  LC Trace of Apo C-I Standard at a Concentration of 5.00mg/dL 
 
 
Figure 32.  LC Trace of Apo C-I Standard at a Concentration of 2.50mg/dL 
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Figure 33.  LC Trace of Apo C-I Standard at a Concentration of 1.25mg/dL 
 
3.1.5.2  Analysis of ESI Spectra 
The mass spectral signature of each apolipoprotein in ESI was also measured to 
look for patterns between control and CAD samples.  The ESI spectra for the apo A-I 
standard revealed that multiple charge states between +21 and +39 were generated, with 
the most prominent charge state residing at +32 (Figure 34).  These charge states were 
assigned based on the following formula: 
 
2
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)pJ m mz
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where z1 is the calculated charge state of the unknown ion, J is the number of ions 
selected, m2 is the mass of the peak with the highest m/z in the range selected, m1 is the 
mass of the peak with the lowest m/z in the range selected, and mp is the mass of a 
proton. (Eq. 23)199  This formula was useful in determining the charge state of an 
unknown peak when the protein content of a sample was not known.  However, when 
the protein content of a sample was already known, the charge state of a particular peak 
could more easily be determined. (Eq. 24)199 
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In this equation, M is the mass of the protein peak, z1 is the charge state of a particular 
peak, m1 is the m/z of a particular peak, and mp is the mass of a proton.  Once the charge 
states of all peaks were determined for a given protein, the average mass of the peak 
could be calculated.  The mass of the molecular ion was determined by multiplying the 
m/z for the ion by its charge state.  The mass of the molecular ion from each of the 
charge states was then added together, and an average mass was then calculated. (Eq. 25) 
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In this equation, the average mass of the molecular ion Mavg was calculated by dividing 
the mass of the protein peak (M) at each charge state and then dividing by the total 
number of charge states observed (J).  For the dominant ion of apo A-I, the m/z of 19 
different charge states were observed, and the average m/z calculated to 28081.72 Da 
with a RSD% of 0.01.  This mass was higher than the literature value for apo A-I by 3.12 
mass units. 
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Figure 34.  ESI Spectra for a Standard of Apo A-I at a Concentration of 50.0mg/dL 
 
It was seen that there were several modifications of apo A-I in the standard 
sample due to the distribution of peaks at each charge state.  The complexity of the 
spectra warranted further inspection, so three separate zones were focused upon in order 
to look at the finer structure of the distribution of peaks in the apo A-I standard.  At a 
high charge state, the distribution of the apo A-I peak pattern appeared as four masses, 
with the dominant peak corresponding to the literature mass of apo A-I (Figure 35).  The 
presence of a lower molecular weight ion suggested that a truncated form of apo A-I 
existed in the standard.  There were also two peaks at a higher m/z than the most 
abundant mass, suggesting that either adduct formation occurred or that there were post-
translational modifications of apo A-I that added mass to its structure.   
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Figure 35.  High ESI Charge States for a Standard of Apo A-I at a Concentration of 
50.0mg/dL 
 
 For the zone centered about the most prominent ion of apo A-I, +32, five peaks 
were seen, with one below the dominant ion, and three above (Figure 36).  The high 
charge state region also displayed a complicated spectrum, with as many as eight peaks, 
all of which were higher than the m/z of the dominant ion (Figure 37).  The ion having a 
lower molecular weight than the dominant ion did not appear in the low charge state 
region of the spectrum. 
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Figure 36.  Most Prominent ESI Charge States for a Standard of Apo A-I at a 
Concentration of 50.0mg/dL 
 
 
Figure 37.  Low ESI Charge States for a Standard of Apo A-I at a Concentration of 
50.0mg/dL 
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Over the entire range of the ESI spectra, there were 11 charge states observed in 
total observed for the dominant ion of apo A-I, and increasingly higher numbers of peaks 
of apo A-I as the number of charge states decreased (Table 11).  The dominant ion is in 
bold font, ions that are smaller than the dominant ion have a negative Δ m/z, and ions 
that are larger have a positive Δ m/z value.  For the ions with a higher m/z than the 
dominant peak, the mass difference for each subsequent peak increased by 
approximately 112-114 Da.  Trifluoroacetic acid (TFA) has a molecular weight of 
114.03 g/mol and was used in the solid phase extraction steps for the desalting and 
delipidating of the apolipoprotein samples, as well as in serial dilutions of the standard 
samples.  From this observation, it was ascertained that adducts between apo A-I and 
TFA must have formed.  It was also intriguing that more peaks were observed in the low 
charge state region of the spectrum.  Ions of apo A-I in the low charge state region of the 
spectrum have a higher proton affinity than those with higher charge states, so adduct 
formation should more readily occur in the low charge state region.  As the mass of the 
ions increased, subsequently more TFA adducts were observed to cause the increase in 
mass.  Mass accuracy appeared to be very good up to a m/z ratio of 28678.02 Da, 
wherein the calculated number of TFA adducts began to deviate from whole number 
values.  This was likely due to a lower precision at the higher mass range.  The ion with 
a mass smaller than the dominant ion was likely a truncated form of apo A-I. 
 
Table 11.  Summary of Apo A-I ESI Calculations 
Ion Number Ion (m/z) Δ m/z of Dominant Ion (Δ m/z) / (MW of TFA) 
1 28,081.72 0.00 0.00 
2 27,960.23 -121.49 -- 
3 28,196.47 114.75 1.01 
4 28,310.13 228.41 2.00 
5 28,424.19 342.48 3.00 
6 28,538.20 456.49 4.00 
7 28,678.02 596.31 5.23 
8 28,789.74 708.02 6.21 
9 28,903.00 821.28 7.20 
10 29,014.08 932.36 8.18 
11 29,126.16 1044.44 9.16 
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 The ESI spectra for apo A-II revealed that multiple charge states between +11 
and +20 were generated, with the most prominent charge state residing at +14 (Figure 
38).  Looking at differences in the ESI spectra between apo A-II and apo A-I, the first 
major difference was that that were much fewer ions formed than in the apo A-II spectra.  
The number of charge states was roughly half of that seen with apo A-I, and the degree 
of charge in apo A-II ions ranged from +11 to +20 as opposed to the much higher values 
seen with apo A-I.  This was a surprising result considering apo A-II exists as both a 
dimer and a monomer.  It was originally expected that apo A-II would have a more 
complicated ESI spectra because it existed in both forms, but its spectra contained a total 
of only five peaks.  Two peaks had an average m/z lower than the dominant ion, and two 
peaks had average m/z that were higher. The distribution of ions for apo A-II also 
appeared to favor higher charge states over lower ones.  The average mass was 
determined for apo A-II in the same manner as for apo A-I and was found to be 
17,253.58 Da, with a RSD% less than 0.01.   This mass was lower than the literature 
value for apo A-II by 126.22 mass units. 
 
 
Figure 38.  ESI Spectra for a Sample of Apo A-II 
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 In the ESI spectra focused on the high charge state, prominent charge state, and 
low charge state regions, apo A-II appeared to be distributed more symmetrically around 
the most abundant mass than was seen with apo A-I (Figures 39-41).   
 
 
Figure 39.  High ESI Charge States for a Sample of Apo A-II 
 
 
Figure 40.  Most Prominent ESI Charge States for a Sample of Apo A-II 
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Figure 41.  Low ESI Charge States for a Sample of Apo A-II 
 
Over the entire range of the ESI spectra, there were 5 charge states observed in total for 
the dominant ion of apo A-II, and increasingly higher numbers of peaks of apo A-II as 
the number of charge states decreased (Table 12).  The dominant ion is in bold font, ions 
that are smaller than the dominant ion have a negative Δ m/z, and larger ions have a 
positive Δ m/z value.  Looking at differences in m/z ratios, an average difference was 
calculated of approximately 110-129 Da for each subsequent peak, which did not 
correlate well with the molecular weight of TFA as was previously seen with apo A-I.  
This observation revealed that the distribution of peaks in the ESI spectra of apo A-II 
were more likely to be post-translational modifications, and not adducts of TFA. 
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Table 12.  Summary of Apo A-II ESI Calculations 
Ion Number Ion (m/z) Δ m/z of Dominant Ion (Δ m/z) / (MW of TFA) 
1 17,253.58 0.00 0.00 
2 17,125.37 -128.21 -- 
3 17,024.59 -228.99 -- 
4 17,382.41 128.83 1.13 
5 17,491.07 237.49 2.08 
 
 Of the three apolipoproteins analyzed by LC-MS, the apo C-I standard had the 
least complex ESI spectra although it was observed to be asymmetric with regards to the 
dominant ion (Figure 42).  The spectrum was not as convoluted as the other 
apolipoproteins so focusing on specific regions to reveal peak structure was not 
necessary in this case.  Only a single peak existed that had a lower m/z than the 
dominant ion, and the remaining five peaks had a higher m/z ratio.     
 
 
Figure 42.  ESI Spectra for a Standard of Apo C-I at a Concentration of 5.00mg/dL 
 
The charge states ranged from +4 to +8, and the charge state at +7 was observed to be 
the most prevalent ion.  The highest number of peaks was seen in the region with a 
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charge state of +5.  The average mass was determined for apo C-I in the same manner as 
for apo A-I and apo A-II and was found to be 6630.39 Da, with a RSD% of 0.01.  This 
mass was lower than the literature value for apo C-I mass by 0.21 mass units.  The ion 
with a lower m/z than the dominant ion differed by 197 Da and ions with a higher m/z 
increased in mass by increments of 110-120 Da (Table 13).   
 
Table 13.  Summary of Apo C-I ESI Calculations 
Ion Number Ion (m/z) Δ m/z of Dominant Ion (Δ m/z) / (MW of TFA) 
1 6,630.39 0.00 0.00 
2 6,432.92 -197.47 -- 
3 6,740.15 109.76 0.96 
4 6,861.31 230.93 2.02 
5 6,973.80 343.42 3.01 
6 7,087.42 457.03 4.01 
7 7,201.43 571.05 5.01 
 
 Analysis of the ESI spectra in detail enabled correct classification of the different 
apolipoprotein peaks in the patient samples, and offered a means to compare peak 
distribution and intensity between different samples.  For the twelve patient samples, 
there were not significant density-dependent or patient-dependent differences in the ESI 
spectra of apo A-I in numbers of post-translational modifications that could be seen 
(Figure 43).  However, there were observable differences in the peak intensities between 
samples. 
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Figure 43.  ESI Spectra of Apo A-I for (A) CAD HDL-2, (B) CAD HDL-3, (C) Control 
HDL-2, and (D) Control HDL-3 
 
 With a more detailed look at the three selected zones, differences between the 
control group and the CAD group could more easily be determined (Figures 44-46).  In 
every case, the HDL-2 and HDL-3 fractions for both cohorts appeared to contain the 
same number of peaks at the same masses as one another, indicating that adduct 
formation of TFA with the apolipoproteins behaved similarly for both cohorts.  A subtle 
difference could be seen when comparing the intensity of the ion to the left of the 
predominant peak for both the control and CAD groups.  It was observed that this ion 
was in lower abundance in the CAD samples than in the controls, and this observation 
was consistent across the entire ESI spectrum.  The most dramatic example of this was 
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seen in the low charge state region of the ESI spectrum, where this ion was not detected 
at all in the CAD group, but gave a good signal in the control group.  This ion was 
calculated to be 121.49 Da smaller than the dominant ion of Apo A-I, and indicated that 
a truncated form of apo A-I was more prevalent in the control group.  Previous research 
in our laboratory identified a truncated form of apo A-I, designated as apo A-I’ and 
having a mass of 27974.84 Da, which was 14.61 Da smaller than the mass reported here. 
 
 
Figure 44.  ESI Spectra of High Charge States of Apo A-I for (A) CAD HDL-2, (B) 
CAD HDL-3, (C) Control HDL-2, and (D) Control HDL-3 
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Figure 45.  ESI Spectra of the Most Prominent Charge States of Apo A-I for (A) CAD 
HDL-2, (B) CAD HDL-3, (C) Control HDL-2, and (D) Control HDL-3 
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Figure 46.  ESI Spectra of Low Charge States of Apo A-I for (A) CAD HDL-2, (B) 
CAD HDL-3, (C) Control HDL-2, and (D) Control HDL-3 
 
 A considerable difference was seen between density-distinct subclasses for 
control and CAD subjects in the analysis of apo A-2 by ESI.  A significant increase in 
the intensity of the peaks was observed in the HDL-3 fractions of both the control and 
the CAD sample.  This result correlated well with literature that explains that particles 
containing both apo A-I and apo A-II are predominately present in HDL-3.200  A 
surprising feature of the apo A-II analysis by ESI was that the HDL-3 spectrum for the 
CAD patient was shifted towards higher charge states while the HDL-2 fraction from the 
CAD patient and both of the control fractions displayed similar charge state 
distributions.  Beyond the shifting of the charge states, the distribution of peaks for each 
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was largely the same and can be viewed in the appended data section.  This result 
demonstrated that patient-to-patient variability can have a large impact on the analysis. 
 
 
Figure 47.  ESI Spectra of Apo C-I for (A) CAD HDL-2, (B) CAD HDL-3, (C) Control 
HDL-2, and (D) Control HDL-3 
 
The ESI spectra of apo C-I also displayed a large variation in the distribution of 
charge states that appeared to be dependent on whether the sample was a control or a 
CAD subject (Figure 47).  The most prominent ion in the apo C-I standard and in both 
HDL-2 and HDL-3 of the control sample appeared at a charge state of +7.  In the CAD 
subject, the +8 charge state was nearly equally predominant with the +7 ion in the HDL-
2 fraction and very predominant in the HDL-3 fraction.  This information indicated that 
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apo C-I from CAD samples had a higher proton affinity than those found in control 
samples.  The intensity of the truncated form of apo C-I’ peak also appeared to scale 
with the intensity of the apo C-I peak and was consistently observed at approximately 
one-third of its height. 
 
3.1.5.3  Identification and Quantification of HDL Apolipoproteins by Ion Extraction 
A novel function of the Q-Star LC-MS software was the ability to isolate known 
ions of a particular protein from the total ion current for simplified quantification.  This 
entailed choosing an m/z value that correlated with the average molecular mass for each 
apolipoprotein and dividing by the charge state of the most abundant ion.  In the LC 
trace for the apolipoprotein standards, there appeared to be an abundance of impurities 
that masked the peaks for the apolipoproteins themselves, but the use of ion-extraction 
generated a much cleaner spectra.  This entailed filtering out ions that did not have the 
correct m/z, so that only the ions of interest were displayed (Table 14).   
 
Table 14.  Ion Extractions for Apolipoproteins A-I, A-II, and C-I 
Apolipoprotein Avg. MW Most Abundant Ion Ion Extraction 
Apo A-I 28,078.60 +32 877.46 
Apo A-II 17,379.94 +14 1,241.42 
Apo C-I 6,630.60 +7 947.23 
 
As with the LC traces, Origin software was again utilized to integrate the spectra 
to link the concentration of the standards with the instrument response (Figures 48-53).  
Of note, is that in the apo A-I standard, a doublet appeared to exist in the ion extraction 
trace, indicating that there likely were post-translational modifications of apo A-I 
contained in the commercial standard.  In the apo C-I standard, only a singlet peak was 
seen, indicating that either the standard contained only a single mass for apo C-I, or that 
the concentration was sufficiently low to prevent seeing a second mass peak. 
The lowest concentration of apo A-I that was visible in the ion extraction trace was 
62.5μg/mL, while the lowest concentration of apo C-I was 25.0μg/mL.  The integrated 
areas of apo A-I appeared to track well with concentration, whereas changing the 
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concentration of apo C-I by a factor of two drastically reduced the instrument response 
by nearly a factor of five.  The quantification based on ion extraction, while an 
improvement over quantification based on the LC trace, still has limitations.   
By dividing the molecular weight of each apolipoprotein by the charge state of its 
most abundant mass, the instrumental response will be biased towards only the most 
abundant ion.  For example, the m/z values for the +32 charge state of apo A-I ranged 
from 873.76 to 910.19 Da, and also ranged from 918.49 to 1028.78 Da for the +7 charge 
state of apo C-I.  Selecting the most abundant ions for each respective apolipoprotein 
served to filter out much of the background noise seen in the LC trace, but also altered 
the intensity of peaks that were filtered out.  In cases where multiple adducts of TFA 
were observed, the high MW ions were filtered out of the resulting spectrum through 
selection of the most abundant ions of the two apolipoproteins.  By combining the 
adduct formation between TFA and the apolipoproteins, and choosing a narrow mass 
window around the most abundant ions of each, the concentration of the two 
apolipoproteins were expected to be underestimated. 
  
 
Figure 48.  Ion Extraction of Apo A-I Standard at a Concentration of 50.0mg/dL 
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Figure 49.  Ion Extraction of Apo A-I Standard at a Concentration of 25.0mg/dL 
 
 
Figure 50.  Ion Extraction of Apo A-I Standard at a Concentration of 12.5mg/dL 
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Figure 51.  Ion Extraction of Apo A-I Standard at a Concentration of 6.25mg/dL 
 
 
Figure 52.  Ion Extraction of Apo C-I Standard at a Concentration of 5.00mg/dL 
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Figure 53.  Ion Extraction of Apo C-I Standard at a Concentration of 2.50mg/dL 
 
 Calibration curves were generated for both the LC traces and ion extraction 
traces for the apo A-I and apo C-I standards in order to determine the level of 
quantification with both methods.  It was seen that there was a very high background in 
the LC-traces for both apolipoproteins, as determined by the large y-intercept of the 
calibration curve (Figures 54,55).  The relationship between the instrument response and 
concentration appeared to track fairly well despite the high background.  As for the ion 
extraction calibration curves, the background was greatly reduced, but the instrument 
response was not as linear as in the LC mode (Figures 56,57).  The effect of extracting 
only the ions of interest diminished the background current of any co-eluting ions, but 
selection of ions likely played a large role in quantifying the amount of apo A-I or apo 
C-I that was detected.  This was seen very well in the calibration for apo C-I because the 
instrument response dropped nearly a factor of five for a two-fold decrease in 
concentration.  Dividing the average mass of apo C-I (6630.60 Da) by its most abundant 
ion (+7), resulted in an ion extraction value of 947.23 Da.  A narrow mass window 
around this predominant ion would filter out the truncated form of apo C-I possessing an 
average mass of 6430.60 Da, and an extracted value of 918.66 Da.  Because the 
truncated apo C-I ions would not be present in the ion extraction trace, the resulting 
value for the integrated intensity would be lower than expected. 
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Figure 54.  Calibration of Apo A-I by LC Trace 
 
 
Figure 55.  Calibration of Apo C-I by LC Trace 
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Figure 56.  Calibration of Apo A-I by Ion Extraction 
 
 
Figure 57.  Calibration of Apo C-I by Ion Extraction 
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3.1.5.4  Comparison of Patient Samples 
LC-MS was chosen as one of the methods for secondary analysis following 
preparative UC in order to determine what, if any, differences existed between two HDL 
subclasses in known CAD samples and control samples.  Qualitatively, it was of interest 
to determine if different mass distributions of apolipoproteins were visible based on their 
density or which of the two cohorts the sample belonged to. Quantitatively, the focus 
was to determine whether differences could be seen in the relative abundance of apo A-I 
and the hypothesized atherogenic apo C-I.   
Three patients from each cohort were selected, and preparative UC was used in 
order to selectively remove the buoyant HDL-2 and dense HDL-3 subclasses from the 
rest of the serum profile.  SPE was performed on these fractions, which were then 
reconstituted in 100μL of 0.1% TFA/H2O for the LC-MS experiment.  In total, twelve 
samples were then analyzed by LC-MS (Figures 42-47).  It was observed that the order 
the apolipoproteins eluted from the reverse phase LC column followed what was 
previously seen with the reverse phase SPE column, with the most hydrophobic 
apolipoproteins requiring the longest amount of time to elute.  Any HSA that was not 
successfully washed off the column during the SPE procedure eluted early in the LC 
trace.  Apo C-I eluted as a doublet with the first peak appearing very broad, while the 
second very sharp in comparison.  Apo A-I eluted as a tall peak with a shoulder on the 
left side that could not be identified.  The more hydrophobic apo A-II eluted after the 
other apolipoproteins at an intermediate intensity between apo C-I and apo A-I.  Any 
small molecular weight lipids that were successfully eluted during SPE, eluted after the 
apo A-II peak.  These peaks were designated as lipids because they were the most 
hydrophobic portion of the samples and also because they had a much lower observed 
molecular weight than the apolipoproteins. 
There were a few striking differences between samples of HDL-2 and HDL-3 in 
the LC traces.  When HSA was visible, it appeared to be more pronounced in the HDL-3 
fraction, as was the case for every sample except for sample 10.  The presence of lipids 
was also more prevalent in samples of HDL-2.  The peak shapes for the apolipoproteins 
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were largely the same throughout the entire batch of samples, but it was clear that the 
intensities fluctuated greatly between samples.  Quantification was performed by 
integrating the area under each apolipoprotein in Origin software and comparing the 
integrated intensity to the calibration curves previously established. 
  From the LC traces, ion extraction traces were generated by isolating the most 
prominent charge states for the apolipoproteins, then using Origin software in order to 
plot them on the same axis (Figures 58, 59).  This presentation gave a better picture of 
the distribution of the apolipoproteins by minimizing the background noise of the LC 
trace.  Though it was not necessary in this case, this feature could have been used to help 
identify the most probable migration time for molecules in the sample if the LC trace 
includes peaks that co-elute but formed different ions during electrospray.  In all cases, 
the apolipoproteins in the ion extraction traces were seen as very sharp single peaks.  
Note also that the peaks for HSA and any lipids are completely missing from the original 
LC trace.  This occurred because the ions formed by ESI of both the HSA and the lipids 
were filtered out by the choice of ions to be used in the ion extraction.  Quantification 
was performed by integrating the area under each apolipoprotein in Origin software and 
comparing the integrated intensity to the calibration curves previously established. 
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Figure 58.  LC Total Ion Current and Ion Extractions for Sample #47 
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Figure 59.  LC Total Ion Current and Ion Extractions for Sample #10 
 
 By comparing the twelve samples to the calibration curves for both the LC trace 
and the ion extraction trace, the relative amounts of apo A-I and apo C-I were calculated 
(Figures 60, 61).  From the concentration of each apolipoprotein in mg/dL, the MW of 
each and the volume of serum samples could be used to determine the number of moles 
of each apolipoprotein.  This experiment was designed to determine if the amount of apo 
C-I can be linked to whether a sample is a control or CAD, so the number of moles of 
apo C-I were divided by the number of moles of apo A-I to give a means of comparing 
the samples against one another.   
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Figure 60.  Quantification of Apolipoproteins by LC Trace 
 
 
Figure 61.  Quantification of Apolipoproteins by Ion Extraction 
 
By definition, an HDL particle must contain at least one apo A-I, but does not 
necessarily have to contain apo C-I, so this ratio yielded information regarding the 
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stoichiometry between the two apolipoproteins.  On a mole-to-mole ratio between apo 
C-1 and apo A-1 in a normo-lipidemic sample, this ratio was expected to be between 
0.169 and 0.254.  In other words, approximately one in five HDL particles should have 
both apo A-I and apo C-I.  Looking at the reported values for the calibration based on 
the LC trace, several samples had an apo C-I to apo A-I ratio that was barely above zero, 
one sample that was at the expected ratio, and three samples that had a much higher than 
expected ratio.  This was not surprising given that the very high background in the LC 
trace would negatively effect the calibration.  Looking at the reported values for the 
calibration based on ion extraction, however, about seven of the twelve samples had 
ratios in range of the expected ratio, while the remaining five had ratios that were much 
higher than expected.  The better signal/noise in the ion extraction traces accounted for 
the better quantification than looking at the LC trace alone, but ionization efficiency 
should be expected to play a role in the quality of these values.  As a result, 
quantification by LC-MS generated a rough assessment of the apolipoprotein content of 
the HDL samples. 
 
3.1.6   CE Analysis of HDL Fractions 
Capillary Electrophoresis (CE) was another method chosen for secondary 
analysis following preparative UC in order to determine if there were differences in the 
electrophoretic properties between HDL subclasses in known CAD samples and control 
samples.  Qualitatively, it was of interest to determine whether post-translational 
modifications could be detected by changes in the inherent mobility of the 
apolipoproteins of HDL in these samples.  Another goal focused on analyzing the 
differences in distributions of the various apolipoproteins as a function of density. 
Quantitatively, the focus was to determine whether differences could be seen in the 
relative abundance of apo A-I and the hypothesized atherogenic apo C-I throughout the 
selected samples.   
Three patients from each cohort were selected, and preparative UC was used in 
order to selectively remove the buoyant HDL-2 and dense HDL-3 subclasses from the 
 115
rest of the serum profile.  SPE was performed on these fractions, which were then 
reconstituted in 100μL of a CE buffer consisting of 12.5mM sodium borate, 3.5mM 
SDS, and 20% (v/v) ACN.  This buffer system was chosen in order give a strong EOF, 
due to the high pH of approximately 9.00, and to ensure a high amount of negative 
charge on the apolipoprotein particles due to their interaction with the anionic surfactant.  
These conditions served to minimize apolipoprotein/apolipoprotein interactions and 
apolipoprotein wall interactions.  The electrophoresis experiment was performed in 
normal polarity, such that the electroosmotic flow (EOF) moves from the anode to the 
cathode.  Integration of peak areas was performed manually.  In total, twelve samples 
were analyzed by CE. 
 
3.1.6.1  Identification and Quantification of HDL Apolipoproteins by CE 
Serial dilutions were performed on stock 1.000mg/mL standard solutions of apo 
A-1 and apo C-1 in order to generate a concentration range that would include the 
dynamic range of each apolipoprotein expected in a serum sample.  The average molar 
concentration of apo C-I is a factor of twenty times less than that of apo A-I in normo-
lipidemic serum, which was reflected in the establishment of these calibration curves 
(Figures 62-65).  In these figures, the electropherograms for each dilution of apo A-I and 
apo C-I were staggered in order to better visualize the peak shapes at each concentration. 
The migration times of the EOF marker and both of the apolipoprotein standards did not 
fluctuate during the construction of the calibration curve. 
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Figure 62.  Electropherograms for Apo A-I Calibration.  Conditions:  12.5mM Sodium 
Borate, 3.5mM SDS (70%), 20% (v/v) ACN, 5s Injection, 17.5kV 
 
 
Figure 63.  Apo A-I Calibration Curve by CE 
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Figure 64.  Electropherograms for Apo C-I Calibration.  Conditions as Above 
 
 
Figure 65.  Apo C-I Calibration Curve by CE 
 
 In these curves the neutral marker, labeled EOF, eluted past the detector at 
approximately 5 minutes, apo A-I eluted at approximately 11.5 minutes, and apo C-I 
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eluted at approximately 13.5 minutes.  By combining the migration time of the neutral 
marker, the migration time of analyte ions, and the dimensions of the capillary, the 
mobility of these species could be determined.  The mobility for the apolipoproteins in 
the standards was found to be -25.9 x10-5cm2/Vs and -28.9 x10-5cm2/Vs for apo A-I and 
apo C-I respectively.  Integration of the peak areas was performed manually.  The 
calibration curves showed a strong linear relationship between concentration and UV 
absorbance over the selected concentration range for both apolipoproteins.  The 
corrected area (Corr Area) of peaks that migrated past the detector was calculated as a 
function of the integrated area and velocity of the peaks, length to the detector (LD) in 
cm, and the migration time of the peak (tM) in seconds, as they eluted through the 
capillary. (Eq. 26)   
 
( ) ( )D
M
LCorr Area Area
t
= ×        (26) 
 
The corrected area accounts for peak widening that occurred to ions that took 
longer to migrate past the detector, and prevented the instrument from reporting higher 
areas for the slower moving peaks. 
 
3.1.6.2 Comparison of Patient Samples 
It was observed that the order the apolipoproteins eluted from capillary column 
differed from what was seen in both SPE and LC-MS.  Because this was not a 
chromatography experiment, the apolipoproteins were separated by differences in 
electrophoretic mobility, dictated by their size/charge ratio.  Larger particles with low 
charges were expected to have lower mobilities than small particles that were highly 
charged.  These CE experiments were performed in normal polarity, so the only ions that 
reached the detector were anions that possessed a lower mobility than the EOF marker.  
In a sense, anions with mobilities lower than the EOF were driven by electrophoresis to 
the anode, but were pulled by electroosmosis past the detector to the cathode.  The 
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balance between size and charge can be used to explain the elution order of the 
apolipoproteins.  The observed elution order of peaks in the electropherograms was:  
EOF marker, HSA, apo A-II, a mixture of apo C-II/C-III, followed by apo A-I, then 
finally apo C-I.  The elution profile of these apolipoprotein samples correlated well with 
data previously obtained in our laboratory.201  This could also be explained in part by 
mass spectrometry results that gave details on the size/charge of these various 
apolipoproteins.  HSA is larger than any of the apolipoproteins of HDL (~66 kDa) and 
also had a high number of charge states.  Its large size kept its mobility low compared to 
the other apolipoproteins.  Apo A-I was the next largest apolipoprotein (~28 kDa), but 
displayed a high number of charge states in ESI.  This combination of size and charge 
explained why apo A-I had a higher mobility than every other apolipoprotein except for 
apo C-I.  Though apo C-I formed very low charge states by ESI, its MW is much lower 
than the other lipoproteins (~6.6 kDa), which explained its relatively high mobility.  Apo 
A-II displayed more charge states in ESI than apo C-I, but less that apo A-I and it also 
possessed an intermediate MW between apo A-I and apo C-I (~17.5 kDa).  This 
combination of size and charge gave Apo A-II an intermediate mobility between apo A-I 
and apo C-I.   
There were a few striking differences between samples of HDL-2 and HDL-3 for 
the two patient cohorts in the resulting electropherograms (Figures 66-67).  The peak 
shapes for the apolipoproteins were largely the same throughout the entire batch of 
samples, but it was clear that the intensities fluctuated greatly between both patients and 
density regions.  Any HSA that was not successfully washed off the column during the 
SPE procedure was typically seen as a broad peak early in the electropherogram and 
appeared to be more dominant in the HDL-3 fraction.  Apo A-II was typically seen as a 
medium intensity single peak with a fairly broad base.  It appeared to have a more erratic 
peak shape in CAD samples, and typically had a small shoulder peak on the left side.  
The apolipoproteins apo C-II and apo C-III were seen as very small sharp peaks between 
apo A-II and apo A-I and were generally easier to visualize in control samples.  Apo A-I 
eluted as a dominantly tall peak with a shoulder on the right side that could not be 
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identified beyond assumption that it may be a modified version of the apolipoprotein as 
supported by evidence of post-translational modifications seen in both MALDI and ESI 
results.  Apo C-I eluted very late in the electropherogram as a doublet with the first peak 
appearing sharper than the later peak.  Because apo C-I has a known truncated form of 
approximately 6.4 kDa, it was hypothesized that the later of the two peaks for apo C-I 
was the truncated form because its lower size should give it a higher mobility.  Mass 
spectral data also indicated that the truncated apo C-I’ had a lower intensity than the 
native apo C-I, which further verified this hypothesis.  Because of the low intensity of 
apo C-I relative to the other apolipoproteins, a zoomed in view of that region of the 
electropherogram was added to each figure to better illustrate this feature.  
Quantification was performed by comparing the calculated corrected areas for each 
apolipoprotein to the generated calibration curves from the standards of apo A-I and apo 
C-I.  Note that both the primary and shoulder peak of apo A-I were integrated together, 
and the two peaks for apo C-I were integrated together for this comparison to the 
standards. 
 
 
Figure 66.  Electropherograms of HDL Fractions for Sample #47.  Conditions as Above 
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Figure 67.  Electropherograms of HDL Fractions for Sample #10.  Conditions as Above 
 
 It was observed that the migration time of the EOF marker appeared to drift 
towards progressively later times over the lifetime of the capillary column.  This peak 
shifting phenomenon was most easily visualized in the analysis of HDL-2 in sample 195 
and HDL-2 of sample 79 as seen in the appended electropherograms.  EOF peak drift did 
not impact classification of the apolipoproteins because the mobility values for each did 
not change, and the corrected area calculation accounted for changes in peak velocity. 
It was originally hypothesized that apo C-I may play a role in the early onset of 
cardiovascular disease, and early studies questioned whether buoyant HDL-2 was 
enriched with this apolipoprotein.  Based on the quantification of apo A-I and apo C-I by 
CE, it was apparent that HDL-2 has a higher concentration of apo C-I relative to apo A-I 
in every sample but one (Figure 68).   
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Figure 68.  Quantification of Apo A-I and Apo C-I by CE 
 
   The mole-to-mole ratio between apo C-1 and apo A-1 in a normo-lipidemic 
sample was expected to be between 0.169 and 0.254 which correlates reasonably well 
with the calculated CE data.  There appeared to be a larger disparity between the 
concentrations of these two apolipoproteins between HDL-2 and HDL-3 in the control 
samples, and a very minor difference between the two density regions in CAD samples.  
Data obtained from the CE gave the best quantification of the apolipoproteins out of the 
methods utilized in this study.  Qualitatively the data indicated that there is a slightly 
higher ratio of apo C-I to apo A-I in the buoyant fraction of HDL, and supported the 
mass spectral evidence of the presence of subclasses of apo A-I and apo C-I. 
  
3.1.7   IEF Analysis of HDL Fractions 
 
3.1.7.1  Identification of HDL Apolipoproteins 
 The immobilized pH Gradient (IPG) gels used in this study gave good resolution 
of the various apolipoproteins of HDL and appeared to reveal several post-translational 
modifications for apo A-I, apo A-II, and apo C-I.  It was observed that for each of these 
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apolipoproteins, there was typically a dominant peak that appeared at a reproducible pI 
value of ranging no more than ±0.10 pI units from sample to sample.  The observed pI 
values correlated fairly well with values that were previously seen in our laboratory.141  
Apo A-I was very easily recognized at a pI value centered about 5.24, as was apo C-I at 
a pI value centered about 6.65.  Apo A-II was not well resolved from the other apo C 
proteins, but was typically seen at a pI value centered about 4.70.  In any samples in 
which the HSA was not fully removed by SPE, a broad peak was seen between pI values 
of 5.60 to 6.00.  Though accurate quantification was not possible, a rough estimation of 
apolipoprotein concentration was determined through comparison of relative peak 
intensities within and between samples.  Observation of the peak qualities throughout the 
cohort of 12 samples revealed that banding in the gels were typically very sharp, with 
very little smearing of bands across the gels.  It was suspected that the loading capacity 
of the gel was likely approached, or even met in some cases, for apo A-I and HSA, as 
evidenced by very dark staining and distortion of band shape in these pI regions.   
 
3.1.7.2 Comparison of Patient Samples 
 When comparing density-dependent regions of HDL and the two cohorts of 
patients, qualitative differences such as the presence/absence of peaks, pI values of 
dominant peaks, and distribution of peaks for a given apolipoprotein were the primary 
focus.  Rough quantification, based on darkness of staining, was useful in determining 
which peaks were the most dominant in each density region for both cohorts of patients.   
Upon initial analysis, each sample revealed a high number of bands across the entire pI 
region, but possessed a particularly complex distribution in the apo A-II and apo A-I 
region (Figures 69, 70).  As expected, it was also seen that HSA was not present in every 
sample, as was the case in both mass spec experiments and in CE electropherograms. 
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Figure 69.  pI Profile for Sample #47 with a 13cm, pH 4-7 IPG Strip 
 
 
Figure 70.  pI Profile for Sample #10 with a 13cm, pH 4-7 IPG Strip 
 
 As few as 5, and as many as 7 bands were seen for apo A-I, which correlates well 
with what was seen in the MALDI and LC-MS.  Two dominant peaks existed at pI 
values of approximately 5.23 and 5.32 in the majority of the samples.  There was a 
medium intensity band at a more basic pI value of between 5.36 and 5.46 that was 
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common across the 12 samples as well.  Only in the more acidic region at pI values 
between 5.05 and 5.20 did differences between samples particularly begin to stand out.   
 Apo A-II was primarily visualized at a pI value of approximately 4.75 throughout 
the various samples.  A single more basic band was seen at a pI range of 4.80 to 4.90 and 
several more acidic bands between 4.50 and 4.70.  This apolipoprotein was more 
predominant in fractions of HDL-3, which agrees with literature observations that the 
majority of apo A-II was reported to be found in dense HDL.202 
 The analysis of apo C-I was much more informative than the other 
apolipoproteins.  In some cases, only a single pI value was observed, but as many as 4 
were seen.  Contrary to what was observed in the other methods, the bands 
corresponding to apo C-I appeared to be more intense in the dense HDL-3 fractions than 
in the buoyant HDL-2.  However, the concentration of apo C-I must be compared to the 
concentration of apo A-I in order to determine if it is indeed enriched with apo C-I.  
Since quantification with this technique was not possible, the distribution of pI values 
will yield much more meaningful information. The three CAD samples, displayed 
markedly different apo C-I pI banding from one another and from the controls.  The 
banding pattern in sample 10 revealed a single dominant apo C-I peak at a pI value of 
6.66 in both HDL-2 and HDL-3.  Sample 170 displayed very minimal peaks for apo C-I, 
with a singlet in HDL-2 and a doublet in HDL-3.  There were several apparent modified 
versions of apo C-I in sample 195, which showed three medium intensity bands at pI 
values between 6.60 and 6.86 in HDL-2 and more basic pI values in HDL-3.  The 
control samples, with the exception of sample 49, displayed low intensity bands for apo 
C-I, particularly in the HDL-2 fraction.  Sample 49 however, showed a very intense 
triplicate of apo C-I bands in the HDL-3 fraction with pI values at 6.61, 6.67, and 6.79. 
 The most striking difference between the CAD and control samples appeared to 
be differences in apo C-I intensity and distribution between the two HDL fractions.  
Banding patterns for apo A-I and apo A-II tended to vary less between patient samples 
and density regions than apo C-I and did not offer a great deal of insight as to differences 
between the two sample cohorts.  Control samples were observed to display only very 
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minor bands for apo C-I in the HDL-2 fraction, but much more intense bands in the 
HDL-3 fraction.  CAD samples on the other hand, tended to display similarly intense 
bands for apo C-I in both HDL fractions, which was particularly true with samples 10 
and 195.  This result gave further evidence that there is both a quantitative and 
qualitative difference in the apolipoprotein distribution found in density-distinct 
subclasses from the two patient cohorts.   
 
3.2  Clinical Studies 
3.2.1   Aortic Smooth Muscle Cell Apoptosis 
The Chatterjee laboratory at The Johns Hopkins University, was responsible for 
analyzing the apoptotic capacity of samples of HDL that were generated by means of 
preparative UC.  Samples of HDL-2 and HDL-3 were isolated and then desalted and 
sterilized as described in the materials and methods section prior to shipment.  It was 
previously seen that HDL particles enriched in apo C-I from the cord blood of infants 
markedly induced apoptosis via the N-SMase pathway.186  The mitochondria within cells 
releases cytochrome C in response to pro-apoptotic stimuli.  This cytochrome C then 
interacts with the inositol triphosphate receptor (IP3R) found in the endoplasmic 
reticulum of the cell, triggering a release of calcium.  Increased calcium levels in turn 
trigger an increased release of cytochrome C by the mitochondria, creating a positive 
feedback loop.  Ultimately, the high cytochrome C levels activate various caspases 
which are responsible for destroying the cell from within. 
Recent analyses of the HDL fractions from patient samples were also observed to 
induce apoptosis involving the same pathway.  By combining 4'-6-Diamidino-2-
phenylindole (DAPI) as a stain of the aortic smooth muscle cell (ASMC) cultures with 
fluorescent antibodies against cytochrome C and caspase-3, the response of the cell 
cultures to outside stimuli could be monitored.  ASMCs were photographed under a 
phase contrast fluorescent microscope in order to visualize any apoptosis-inducing 
interactions (Figure 71).   
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Figure 71.  Activation of Caspase-3 and Cytochrome-C in ASMC by the HDL-2 
Fraction of Sample #10 
 
When the HDL-2 fraction from sample #10 was introduced to the ASMC culture, a 
strong reaction of the fluorescent antibodies towards caspase-3 and cytochrome-C was 
observed.  In the control sample, no noticeable reaction was observed.   
It was discovered that the buoyant HDL-2 fraction from CAD samples readily 
induced apoptosis in ASMCs while HDL-3 fractions from the same patient did not.  
Several hundred cells were counted to determine the number of apoptotic cells (Figure 
72).  Pre-incubation of the ASMC cultures with an inhibitor of N-SMase, GW4869, was 
seen to greatly inhibit apoptosis.  ASMC apoptosis was not seen in either fraction from 
control patients. 
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Figure 72.  Percentage of ASMCs that Underwent Apoptosis after Introduction of 
Samples 
 
3.2.2   Human Arterial Endothelial Cell Apoptosis 
In a related study by the Chatterjee laboratory, the apoptotic effect of LDL and 
HDL fractions was also measured for human arterial endothelial cells (HAEC).  It was 
observed that neither the HDL-2 nor the HDL-3 fraction from CAD samples induced 
HAEC apoptosis.  However, the LDL fraction did induce apoptosis of these cell cultures.  
This result suggested the possibility that small molecules of HDL could penetrate the 
endothelial wall and cause substantial apoptosis of smooth muscle cells.  HAEC were 
also incubated with the HDL-2 fractions from CAD and control samples, and then 
stained with 4’5’-diamino fluoroscein diacetate (DAF-2), which is a marker for nitric 
oxide.  It was seen that the HDL-2 from the CAD samples produced a strongly positive 
reaction as compared to the HDL-2 from a control sample (Figure 73).  Pre-treatment of 
the HAECs with pyrrrolidine dithiocarbamate (PDTC), a membrane permeable anti-
oxidant, was observed to reverse this reaction. 
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Figure 73.  Effects of Serum Lipoproteins on Nitric Oxide Levels 
 
Nitrite is a stable product formed from endothelial nitric oxide synthase (eNOS) 
activity towards nitric oxide.  Measurement of nitrite levels in HAEC using the Greiss 
reagent also suggested that HDL-2 from CAD samples markedly increased nitrite levels, 
which is indicative of increased eNOS activity.203  Since increased levels of nitric oxide 
can induce apoptosis by reaction with superoxides and peroxynitrite generation, it is very 
curious as to why these buoyant samples of HDL-2 induce apoptosis in ASMC but not in 
HAEC. 
 
3.3   Statistical Analysis 
The aim of this study was to determine the feasibility of classifying subjects from 
two groups of samples, controls and CAD, by utilizing a statistical analysis software 
package.  Data from the integrated fluorescence intensities of subclasses contained in 
lipoprotein density profiles was inputted into this software and statistical analyses 
methods were then used to determine which group a particular sample belonged to.  
Classification utilized both linear discriminate analysis (LDA) and sliced average 
variance estimation (SAVE), in which both attempted to determine a linear combination 
of variables.  LDA attempted to find a linear combination of the variables, which in this 
case is the integrated intensities of the various subclasses.  SAVE attempted to find a 
linear combination of the same variables by also using the mean, variance, and 
covariance. In this study, a cohort consisting of 15 controls and 15 CAD samples were 
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analyzed by lipoprotein density profiling that utilized both a 0.2000M solution of NaBiY 
and a 0.2000M solution of Cs2CdY. 
Results from the LDA and SAVE analyses are reported for both solute systems.  
The equations generated by each statistical method were log-transformed functions that 
include the ratios of the most significant variables inputted.  In other words, variables 
that were found to be statistically insignificant contained low exponential values, and 
therefore did not appear in the final equations.  For the 30 patient samples analyzed, the 
resulting LDA equation for NaBiY can be approximated by (Eq. 27), and for Cs2CdY by 
(Eq. 28).  
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( 3 ) ( 2 )3.29log
( 3 ) ( 3) ( 2 )
HDL a HDL bLDA
HDL b LDL HDL a
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For the LDA analysis, the most significant variables were found to be HDL-3a and 
HDL-3b for the NaBiY analysis and LDL-3, HDL-3b, and both TRL subclasses for the 
Cs2CdY analysis.  By simply changing the solute system, the statistical classification 
was observed to dramatically change as a result of the difference in separation achieved 
by each of the solutes.  The NaBiY solute system was capable of separating 12 density-
distinct subclasses in the lipoprotein profile, while Cs2CdY was not able to resolve the 
TRL subclasses from the buoyant LDL subclasses, resulting in only 10 density-distinct 
subclasses.  The dense HDL subclasses of HDL-3a and HDL-3b appeared as significant 
variables in both solute systems, indicating that this region of the lipoprotein profile is 
statistically important in categorizing a sample into one of the two cohorts.  Curiously, 
the LDA analysis determined that HDL-3a was the most important variable in the 
NaBiY separation, while LDL-3 was the most important variable in the Cs2CdY 
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separation.  The difference in weighting of the variables likely occurred due to the lower 
number of resolved subclasses in the Cs2Cdy solute system. 
The SAVE analysis, reported two equations, SAVE1 and SAVE2, in order to 
express the linear combination of variables from each of the two sample groups.  The 
resulting equations for the NaBiY solute system were given by (Eqns. 29 and 30):   
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The resulting equations for the Cs2CdY solute system were given by (Eqns. 31 and 32): 
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For the SAVE1 analysis with the NaBiY solute system, the most significant 
variables were found to be associated with the subclasses HDL-3a and HDL-3b due to 
their high exponent relative to the other subclasses.  Similarly, the most significant 
variables seen in SAVE2 were associated with the subclasses of HDL-3b and HDL3-c.  
This meant that of all of the 12 subclasses analyzed, the fluorescence intensity of the  
dense HDL subclasses influenced the group assignment made by the statistical software 
more heavily than the other variables.  For the SAVE1 analysis with the Cs2CdY solute 
system, the most significant variables were found to be associated with HDL-3a and 
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HDL-3b as was seen in the NaBiY analysis, but HDL-3c was also seen to be statistically 
significant.  The SAVE2 analysis for Cs2CdY however, reported that HDL-3a, LDL-4, 
and b-TRL were all statistically significant.  This result indicated that serum levels of 
two common risk factors for atherogenesis, dense LDL and triglycerides, were important 
in the classification.   
A graphical representation of this data plotted LDA, also known as SIR1, along 
with SAVE1, and SAVE2 (Figures 74, 75).  In these figures the row and column 
determined the axis on which the statistical solution was plotted.  SIR1 was plotted 
against SAVE1 in the upper left panel and against SAVE2 in the upper right panel.  
SAVE1 and SAVE2 were plotted against each other in the bottom right panel.  By 
arranging the data in this manner, each of the three statistical solutions were plotted 
against one another, giving three combinations in a single concise graphic.  The three 
combinations included:  SIR1 vs SAVE1, SIR1 vs. SAVE 2, and SAVE1 vs. SAVE2  
Group 1, the control group, was represented by the black trace, and group 2, the CAD 
group, was represented by the red trace. 
 
 
Figure 74.  Statistical Plots for 6μL of Serum at Saturating NBD (C6-ceramide) 
Conditions, Spun in 0.2000M NaBiY for 6 Hours at 120,000 RPM and 5ºC 
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Figure 75.  Statistical Plots for 6μL of Serum at Saturating NBD (C6-ceramide) 
Conditions, Spun in 0.2000M Cs2CdY for 6 Hours at 120,000 RPM and 5ºC 
 
It was observed that the SAVE1 vs. SAVE2 plots, as seen in the lower right 
panels of each figure, yielded the most discernible classification between the two groups 
for both solute systems.  It was also readily apparent that the difference between the two 
groups was remarkably different when comparing the slopes of the two fitted lines.  The 
values of SAVE1 for the control group were relatively constant over the data range of 
the 15 subjects in this group even though the values for SAVE2 were quite different.  
The inverse appeared to be true for the CAD group, in which SAVE1 drastically 
changed between subjects, while SAVE2 remained relatively constant.  A surprising 
result was seen when the extremities of the two data sets also fell nearly perfectly on 
their respective fitted lines.  Even where the two data sets intersected, there was not 
appreciable deviation of individual data points from their respective classification lines. 
It was also observed that the scatter of the data was considerably better in the 
NaBiY solute system than in the Cs2CdY system.  This largely stemmed from the loss of 
two variables in the Cs2CdY system since the two most buoyant subclasses of LDL 
could not be isolated from the two TRL subclasses.  The best classification appeared in 
the SAVE1 vs. SAVE2 plot of the NaBiY data where two distinct groupings of data 
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were apparent.  The same plot in the Cs2CdY figure was similar in appearance to the 
SAVE1 vs. SAVE2 seen with NaBiY, but there was considerably more scatter in the 
data.  This indicated that a classification was possible with the Cs2CdY system, but it did 
not yield as good of a separation between the two groups.  Comparison of these two 
results indicated that the EDTA solute system chosen for the analysis was an important 
parameter that greatly impacted the end result.  Another important observation is that a 
large distribution of acceptable values for the various subclasses exists that still enabled 
a sample to be correctly classified.     
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CHAPTER IV 
CONCLUSIONS 
 
 The overall objective of this research was to develop a combination of methods 
for an in-depth analysis of the apolipoproteins of HDL subclasses and to apply these 
methods to clinical samples.  This objective was achieved by combining novel density 
gradient separations with secondary analyses that yielded information regarding the size, 
charge, structure, abundance, and distribution of the desired analytes.  By applying these 
methods to a cohort of patients who exhibited a range of cardiovascular health, a better 
assessment of an individual’s cardiovascular risk could be reached, thereby showing 
feasibility for potential early detection of the onset of CAD.   
 The heavy metal EDTA complexes, when used as a solute system in UC, 
generated highly reproducible gradients between individual spins and between different 
batches of solution.  This reproducibility offered a rugged method which allowed a high 
degree of control over the separation of lipoprotein particles, both for fluorometric 
analysis, and for preparative UC.  The use of these solute systems also offered higher 
sample throughput than separations that require time-consuming sequential 
centrifugation steps. 
 Through combination of preparative UC and MALDI-MS, an interesting 
correlation was observed between different density classes of HDL and degrees of post-
translational modifications for its primary apolipoproteins.  There appeared to be 
variable protease activity in the different density regions of HDL which suggests that 
various proteases are also associated with a specific density region of the lipoprotein 
profile. 
 The technique of LC-MS enabled both a qualitative analysis of the distribution of 
apolipoproteins and a semi-quantitative means of determining the concentration of apo 
A-I and apo C-I.  Analysis of the ESI spectra in detail enabled correct classification of 
the different apolipoprotein peaks in the patient samples, and offered a means of 
comparison in terms of numbers of peaks seen in the spectra for each.  For the twelve 
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patient samples, there were no significant density-dependent or patient-dependent 
differences in the ESI spectra of the three apolipoproteins in numbers of post-
translational modifications that could be seen.  Quantification of the apolipoproteins 
throughout the batch of samples provided a rough assessment of apolipoprotein levels 
and indicated that on average, the buoyant HDL-2 fraction possessed a higher relative 
concentration of apo C-I. 
 Based on the quantification of apo A-I and apo C-I by CE, it was apparent that 
fractions of HDL-2 possessed a higher ratio of apo C-I to apo A-I in every sample but 
one.  The relative ratio of these two apolipoproteins also closely agreed with expected 
literature values.  Qualitatively, this experiment also revealed that there were two 
mobility separated components of both apo A-I and apo C-I which correlated with the 
numbers of post-translational modifications seen in MALDI-MS and LC-MS.   
 Gel electrophoresis experiments further revealed the complex nature of the 
apolipoprotein population from various fractions of HDL, and appeared to correlate well 
with results seen in the ESI spectra.  A striking difference was seen in the relative 
abundance of apo C-I between the buoyant and dense fractions of HDL from control and 
CAD samples.  Apo C-I was observed to generate the most intense bands on an IPG gel 
for the buoyant HDL-2 sample for CAD patients and moderately intense bands in the 
dense HDL-3 sample.  Little to no difference was seen when comparing both density 
regions of control patients.  This result further validated the hypothesis that apo C-I 
enriched HDL is found in the buoyant fraction. 
 Cell culture studies from an outside laboratory focused on the capacity of various 
intact HDL fractions to induce apoptosis of both ASMC and HAEC cultures.  It was 
observed that only the buoyant fraction of HDL from CAD samples induced significant 
apoptosis of ASMC.  There was little to no apoptosis in the dense region of HDL from 
CAD samples, or from any fraction of HDL in control samples.  It was also seen that the 
same sample fractions that previously caused significant apoptosis of ASMC induced 
little to no apoptosis of HAEC cultures.  This result yields crucial data about the 
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biological activity of the samples that were previously analyzed by chemical means and 
reveals a possible scheme to explain the instigation of atherogenesis.   
 Statistical analysis demonstrated a new approach at analyzing the compositional 
differences seen in the distribution of lipoproteins with the goal of classifying a patient’s 
risk of developing atherosclerosis.  Despite the array of traditional risk factors, there 
exists a segment of the population that still develops CAD for currently unknown 
reasons.  By combining the separatory power of DGU with EDTA solute systems, 
modern statistical methods have shown a very effective, and nearly perfect, classification 
of two patient cohorts from one another. 
Though the focus of research on lipoproteins has typically centered on the intact 
structure of these particles, as well as quantification of cholesterol levels, the field is 
beginning to shift towards changes in lipoprotein structure itself.  Modifications to either 
the lipid component or in the apolipoproteins themselves have become increasingly 
important, particularly in studies involving the effects of oxidation.  The combination of 
these methods demonstrated strength in their ability to not only quantify the amounts of 
key apolipoproteins, but also to analyze differences in their structure from very different 
perspectives.  The research reported here established a foundation of analytical tools to 
assist in distinguishing differences between healthy samples and those that are at risk of 
developing CAD.  Future applications of this research will explore the use of these 
techniques in determining additional risk factors that can be applied to a broader cohort 
of samples for a more complete assessment of cardiovascular risk. 
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APPENDIX A 
 
  
Figure A1.  Lipoprotein Density Profile of Sample #49 in a 0.2000M Solution of 
NaBiY, Spun for 6 Hours at 120,000 RPM and 5ºC after DS Precipitation 
 
 
Figure A2.  Lipoprotein Density Profile of Sample #79 in a 0.2000M Solution of 
NaBiY, Spun for 6 Hours at 120,000 RPM and 5ºC after DS Precipitation 
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Figure A3.  Lipoprotein Density Profile of Sample #170 in a 0.2000M Solution of 
NaBiY, Spun for 6 Hours at 120,000 RPM and 5ºC after DS Precipitation 
 
 
 
Figure A4.  Lipoprotein Density Profile of Sample #195 in a 0.2000M Solution of 
NaBiY, Spun for 6 Hours at 120,000 RPM and 5ºC after DS Precipitation 
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Figure A5.  ESI Spectra of Apo A-II for (A) CAD HDL-2, (B) CAD HDL-3, (C) 
Control HDL-2, and (D) Control HDL-3 
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Figure A6.  ESI Spectra High Charge States of Apo A-II for (A) CAD HDL-2, (B) CAD 
HDL-3, (C) Control HDL-2, and (D) Control HDL-3 
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Figure A7.  ESI Spectra Most Prominent Charge States of Apo A-II for (A) CAD HDL-
2, (B) CAD HDL-3, (C) Control HDL-2, and (D) Control HDL-3 
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Figure A8.  ESI Spectra Low Charge States of Apo A-II for (A) CAD HDL-2, (B) CAD 
HDL-3, (C) Control HDL-2, and (D) Control HDL-3 
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Figure A9.  LC Total Ion Current for Sample 49 
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Figure A10.  LC Total Ion Current for Sample 79 
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Figure A11.  LC Total Ion Current for Sample 170 
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Figure A12.  LC Total Ion Current for Sample 195 
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Figure A13.  Electropherograms of HDL Fractions for Sample #49 
 
 
Figure A14.  Electropherograms of HDL Fractions for Sample #79 
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Figure A15.  Electropherograms of HDL Fractions for Sample #170 
 
 
Figure A16.  Electropherograms of HDL Fractions for Sample #195 
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Figure A17.  pI Values for Sample #49 
 
 
Figure A18.  pI Values for Sample #79 
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Figure A19.  pI Values for Sample #170 
 
 
Figure A20.  pI Values for Sample #195 
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